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ABSTRACT
Background: Dexmedetomidine is a selective ?2 adrenergic agonist
that attenuates the hemodynamic stress response to tracheal intubation
and extubation, decreases plasma catecholamine concentrations during
surgery and anaesthesia and decreases the perioperative requirements of
anaesthetics and analgesics. Laparoscopic surgeries involve unique
hemodynamic alterations and Dexmedetomidine may serve the role of
an ideal pharmacological adjuvant to obtund these hemodynamic
changes during laparoscopic surgeries.
Objectives: The aim of the study was
(i) To evaluate and compare the analgesic and anaesthetic sparing
properties of two doses of Dexmedetomidine - 0.2 µg/kg/hr and
0.6 µg/kg/hr
(ii) To study the hemodynamic stabilizing properties of two doses of
Dexmedetomidine- 0.2 µg/kg/hr and 0.6 µg/kg/hr
(iii) To study the side effect profile of Dexmedetomidine (bradycardia,
hypotension and increased sedation) for laparoscopic
cholecystectomy.
Methodology: Sixty ASA class I patients aged 18 – 50 years were
randomized into two groups: A and B to receive Dexmedetomidine
infusion at 0.2 µg/kg/hr and 0.6 µg/kg/hr respectively , started 10
minutes before induction of anaesthesia. Inj. Fentanyl at a dose of
1µg/kg was administered before induction of anaesthesia. Anaesthesia
was  induced  with  propofol  2  mg  /  kg  IV  and  muscle  relaxation  was
obtained by Inj. Atracurium at a dose of 0.5 mg/kg. Desflurane was
administered at an inspiratory concentration of 3%. Anaesthesia was
initially maintained with desflurane at 3 % inspired concentrations with
nitrous oxide (3 l / min), oxygen (1.5 l /min) mixture. Intra –operative
HR, SBP, DBP, MAP, SpO2, EtCO2 were recorded every 5 min for first
30 min and subsequently every 10 min intervals till the discontinuation
of anaesthetic drugs. MAP and heart rate values were maintained within
25 % of baseline values by administering fentanyl boluses of 0.5 ug / kg
(up to a maximum of 2 ug / kg) and by varying inspiratory desflurane
concentrations. Total fentanyl requirement, average inspiratory
desflurane concentrations, HR, SBP, DBP, SPO2, ETCO2, post
operative sedation score and intraoperative need for adjuvant such as
propofol were studied.
Results: The two groups showed a statistically significant difference in
total fentanyl requirements and average inspiratory desflurane
concentrations. The requirement of fentanyl was reduced by 20% in the
Dexmedetomidine 0.6 group compared to Dexmedetomidine 0.2 group
in our study. The average inspiratory concentration desflurane required
in group A (Dexmedetomidine 0.2 µg/kg/hr) was 2.66 and the average
inspiratory concentration required in group B (Dexmedetomidine 0.6
µg/kg/hr) was 2.57. Stress response to endotracheal intubation resulted
in an increase in heart rate and MAP values in both the groups though
the degree of increase was lesser in Dexmedetomidine 0.6 group when
compared to Dexmedetomidine 0.2 group. But the values remained
within 25 % of the baseline values and the increase was found not to be
statistically significant. Both the groups did not encounter a significant
increase in heart rate and MAP values on peritoneal insufflations. The
number of hypotensive episodes encountered in Dexmedetomidine 0.6
µg/kg/hr group were found to be significantly higher when compared to
the Dexmedetomidine 0.2 µg/kg/hr group, though these episodes were
transient and could be corrected by a decrease in inspired desflurane
concentration and administration of a fluid bolus. The number of
hypertensive episodes in Dexmedetomidine 0.2 µg/kg/hr group was
significantly higher when compared to Dexmedetomidine 0.6 µg/kg/hr
group and all episodes resolved with fentanyl supplementation.
Dexmedetomidine at 0.6 µg/kg/hr resulted in a progressive increase in
sedation scores and the time to eye opening when compared to
Dexmedetomidine at 0.2 µg/kg/hr.
Conclusion: From this study it was concluded that Dexmedetomidine at
an infusion rate of 0.6 µg/kg/hr has a better analgesic and anaesthetic
sparing property and a better hemodynamic stabilizing property when
compared to an infusion rate of 0.2 µg/kg/hr, with increased episodes of
transient hypotension, increased postoperative sedation score, with no
serious side effects or adverse reactions.
Keywords: Laparoscopy, dexmedetomidine, fentanyl, desflurane,
hypertension, hypotension, tachycardia, bradycardia, sedation,
1CHAPTER 1
INTRODUCTION
This is a modern era of surgery which has witnessed many new
and innovative approaches encompassing minimal intervention.
Laparoscopic surgery occupies the centre stage in this modern era.
Anaesthesiologist of the modern era has to be trained enough to handle
the repercussions of laparoscopy during the perioperative period,
permitting safe and effective patient management while undergoing
laparoscopic surgeries.
Anaesthesiologist’s major concern is to maintain hemodynamic
stability during the course of peri-operative period. Minimally invasive
surgical procedures have seen a remarkable growth in the last decade.
They aim to lessen the trauma of intervention procedures, decrease the
postoperative pain, decrease the duration of stay in hospital, hasten the
return to normal activities and being cost effective, but still capable of
achieving the desired therapeutic result. The first successful
laparoscopic cholecystectomy was performed in 1987 and since then
emerged rapidly as a technique that effectively substituted traditional
open approach to cholecystectomy for symptomatic cholelithiasis.
Laparoscopic surgeries require intraperitoneal insufflations of
CO2 which is associated with significant and unique hemodynamic
2alterations such as reduced stroke volume, elevated blood pressures, and
increase in systemic and pulmonary vascular resistance. There is only a
slight change in the heart rate1.Problems occurring during laparoscopic
techniques are mainly due to combined effects of pneumoperitoneum
with carbon dioxide insufflation and patient positioning , which causes
several hemodynamic and ventilatory changes.
Anaesthesia for laparoscopic cholecystectomy has traditionally
laid emphasis on the use of a variety of pharmacological agents in
different combinations for the purpose of maintenance of hemodynamic
stability. ?2-adrenergic agonists may serve the role of ideal
pharmacological adjuvant for laparoscopic cholecystectomy, as they
provide sedation, anxiolysis, hypnosis, analgesia, and sympatholysis2.
Dexmedetomidine is a highly selective ?2-adrenergic agonist with 1600
times greater selectivity for the ?2 adrenoceptor compared with the ?1
receptor. Dexmedetomidine attenuates the hemodynamic responses to
tracheal intubation and perioperative stress, decreases plasma
catecholamine concentrations during surgery and anaesthesia and
decreases the perioperative requirements of anaesthetics and analgesics.
Various studies have been published, evaluating
Dexmedetomidine administered in various bolus doses for
premedication. However, studies evaluating the effects of
Dexmedetomidine in different dose ranges are essential for the
3administration of the drug as a continuous infusion during surgery.
Because Dexmedetomidine has a high propensity to produce
hypotension and/or bradycardia , various studies are being conducted
worldwide to determine an ideal infusion rate for Dexmedetomidine that
would maximize the anaesthetic and analgesic sparing effects , while at
the same time limiting the occurrence of adverse cardiac effects. This
study is aimed to compare and evaluate the efficacy of
Dexmedetomidine administered in two different doses, in providing
analgesic and anaesthetic sparing effects and in maintaining
hemodynamic stability during laparoscopic cholecystectomy.
4CHAPTER 2
AIM
To evaluate the analgesic and anaesthetic sparing, and
hemodynamic stabilizing properties of two different doses of
Dexmedetomidine - 0.2 µg/kg/hr and 0.6 µg/kg/hr for laparoscopic
cholecystectomy.
5OBJECTIVES
PRIMARY OBJECTIVE
1. To compare the requirement of total opioid (fentanyl) and volatile
anaesthetic (desflurane).
SECONDARY OBJECTIVES
1. To  compare  the  hemodynamic  parameters  (  SBP,  DBP,  MAP,
HR)
2. To study the side effect profile of Dexmedetomidine
(hypotension, bradycardia and increased sedation).
6HISTORY
It was at the beginning of 20th century that the laparoscopic
surgery was first introduced by Dimitri Ott, George Kelling, and Hans
Christian Jacobeus. Ott examined the peritoneal cavity of pregnant
women in 1901, after which a procedure called “koelioscopie “was
performed by George Kelling. In the same year a report called
“Laparothorakoskopie” was published by Jacobeus. Several European
and American authors performed diagnostic laparoscopic procedures in
the following years. With the introduction of cold light fiber-glass
illumination and rod-lens optical system, laparoscopic techniques
became popular among gynecologists. During this period, laparoscopic
technique in the field of general surgery was mainly used for diagnostic
procedures such as diagnosing hepatic disorders and abdominal trauma
until 1983, when the foresight of two surgeons, Lukichev and Muhe lead
them to successfully perform the first laparoscopic cholecystectomy.
They did not receive much attention for their accomplishment and
general surgeons became greatly interested in laparoscopic surgeries
only after the French gynecologist Mouret performed the first
laparoscopic cholecystectomy in 1987 using four trochars. Laparoscopic
surgery has undergone tremendous advancement over past two decades3.
The ?2-adrenergic agonists provide sedation, anxiolysis, hypnosis,
analgesia, and sympatholysis. The initial stimulus for the use of ?2
7agonists erupted from the observations made with the use of clonidine.
Dexmedetomidine is a highly selective ?2 agonist  with  1600  times
greater selectivity for ?2 receptors compared with the ?1 receptors. FDA
in 1999 approved Dexmedetomidine only as a short term sedative for
mechanically ventilated ICU patients (< 24 hours). The drug is now
being used outside the ICU in various settings, including sedation and
adjunct analgesia in the operating room, sedation in various diagnostic
procedures, and for attenuation of withdrawal and detoxification2.
LAPAROSCOPIC SURGERY
Laparoscopic surgeries involve the creation of pneumoperitoneum
and various patient positions that induce pathophysiological changes,
which in turn complicate anaesthetic management. Laparoscopic
surgeries result in alterations in ventilator and respiratory mechanics,
produce various hemodynamic alterations and also cause diverse
physiological disturbances due to patient positioning.
ANAESTHETIC CONSIDERATIONS OF LAPAROSCOPY
(i) VENTILATORY AND RESPIRATORY CHANGES
DURING LAPAROSCOPY
The creation of pneumoperitoneum results in four principle
respiratory disturbances – CO2 subcutaneous emphysema,
pneumothorax, gas embolism and endobronchial intubation4.
8Pneumoperitoneum leads to a decrease in thoracopulmonary
compliance, decrease in functional residual capacity, elevates the
diaphragm and results in atelectasis and causes ventilation – perfusion
mismatch5,  6,  7. PaCO2 progressively increases on the creation of CO2
pneumoperitoneum and reaches a plateau after 15 – 30 minutes of CO2
insufflation. The causes are multifactorial including CO2 absorption
across the peritoneal layers, mechanical causes such as abdominal
distension  by  CO2 pneumoperitoneum, patient positioning and
mechanical ventilation resulting in ventilation perfusion mismatch.
PaCO2 should be maintained within the physiological range by altering
the mechanical ventilation.
CO2 Subcutaneous Emphysema
CO2 subcutaneous emphysema results from accidental
extraperitoneal insufflation of CO2. This condition results in the increase
of VCO2, PaCO2, and PetCO2 8.   CO2 subcutaneous emphysema results
in a progressively increasing PetCO2 that occurs after the PetCO2 value
has plateaued. The degree of increase in VCO2 makes  it  impossible  to
prevent hypercapnia by adjustment of ventilation. Under these
circumstances the procedure is temporarily discontinued and
recommenced after the normalisation of PaCO2 using lower insufflation
pressures. Mechanical ventilation should be continued till the correction
of hypercapnia to prevent increases in work of breathing.
9Pneumothorax, Pneumomediastinum, Pneumopericardium
Pneumoperitoneum may result in the diffusion of gas leading to
pneumomediastinum, pneumothorax and pneumopericardium9,10. These
conditions result in respiratory and hemodynamic disturbances.
Capnothorax leads to increased airway pressures and reduced
thoracopulmonary compliance. VCO2, PaCO2, and PetCO2 all increase
from their baseline values. Alveolar rupture leading to secondary
pneumothorax results in decreased PetCO2 because of decreased cardiac
output. Fall in oxygen saturation and hemodynamic changes should
raise the suspicion of tension pneumothorax. Pneumothorax that occurs
in the absence of pulmonary trauma, by a highly diffusible gas such as
CO2 resolves spontaneously without thoracocentesis. Capnothorax
occurring during laparoscopy can be treated by the application of PEEP,
rather than a chest tube placement11 .Pneumothorax that results from
rupture of bullae, should be treated by thoracocentesis.
10
Figure 1: Diagnosis of respiratory complications during
laparoscopy. ECG, electrocardiographic; Paw, airway pressure;
Petco2, end-tidal carbon dioxide tension.12
Endobronchial Intubation
Pneumoperitoneum causes the diaphragm to move cephalad
which in turn results in cephalad displacement of carina leading to a
potential serious chance of endobronchial intubation. This causes a fall
in oxygen saturation and an increase in airway pressures13.
11
Gas Embolism
Gas embolism by CO2 may result from direct needle puncture into a
blood vessel or trochar placement or direct insufflation into an
abdominal organ. High pressure insufflation of gas at a rapid rate results
in “gas lock” right atrium and vena cava, leading to a decrease in venous
return and cardiac output and resulting in circulatory collapse. Gas
embolism results in a sudden fall in PetCO2 due to decrease in cardiac
output and the resulting enlargement of the physiologic dead space.
Treatment revolves around immediate release of pneumoperitoneum
after the cessation of CO2 insufflation. Patient is placed in Durant (head
down and left lateral) position. Hyperventilation may result in CO2
excretion. Central venous catheter can be introduced and used for
aspiration of gas. Cardiopulmonary resuscitation becomes necessary in
cases of massive embolism and should be initiated early. Hyperbaric
oxygen treatment and cardiopulmonary bypass are used to treat massive
gas embolism14.
(ii) HEMODYNAMIC COMPLICATIONS OF LAPAROSCOPIC
SURGERY
Alterations in hemodynamics are due to changes resulting from
the varied effects of CO2 pneumoperitoneum, positioning of the patient,
anaesthesia and hypercapnia. Hemodynamic changes are characterized
12
by decreased venous return and cardiac output, increase in arterial
pressures and peripheral vascular resistance.
Cardiac output decreases due to multifactorial causes. Venous
return is characterized by a transient increase at low IAPs (< 10 mm
Hg), followed by a decrease15. Progressively increasing IAPs results in
caval compression, venous pooling and increased venous resistance15,16.
Decreases in venous return result in a decreased left ventricular end
diastolic volume. However, cardiac filling pressures are paradoxically
increased by pneumoperitoneum due to increased intrathoracic pressure.
IAPs of up to 15 mm Hg do not cause a significant decrease in ejection
fraction of left ventricle. Pneumoperitoneum and increasing IAPs result
in an increase in peripheral vascular resistance and this is not a reflex
sympathetic response to decreased cardiac output17. This increased
afterload resulting from pneumoperitoneum and increased IAP may
prove detrimental in patients with compromised cardiac status.
13
Figure 2: Schematic representation of CO2 pneumoperitoneum
resulting in decreased cardiac output by various mechanisms
Patient position also significantly alters the systemic vascular
resistance, with Trendelenberg position attenuating the increase, and
head –up position aggravating the increase. The increase in peripheral
vascular resistance is probably mediated by both mechanical and
neurohumoral factors18.
14
Figure 3:  Effects of elevated intra-abdominal pressure
Catecholamines, the renin-angiotensin system, and specifically
vasopressin are released during the presence of pneumoperitoneum,
which may contribute to increase in afterload. Mechanical stimulation of
peritoneal receptors also results in vasopressin release, increased
systemic vascular resistance and increased arterial pressures19.
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(iii) EFFECTS OF PNEUMOPERITONEUM ON REGIONAL
HEMODYNAMICS
Increased intraabdominal pressure and head –up position results
in venous stasis in lower limbs, predisposing to the development of
thromboembolic complications20. Renal function progressively
deteriorates with a fall in urine output, glomerular filtration rate and
renal plasma flow, with increases in intraabdominal pressure21. Cerebral
blood flow velocity increases with CO2 insufflation. But with the
maintenance of normocarbia, pneumoperitoneum along with the head –
down position does not induce harmful alterations in intracranial
hemodynamics22.
(iv) ARRHYTHMIAS DURING LAPAROSCOPY
Cardiac arrhythmias occur due to several reasons during
laparoscopy. CO2 insufflation causes stretching of peritoneum, leading
to reflex increase in vagal tone which produces bradycardia, cardiac
arrhythmias and asystole23. This reflex vagal stimulation is accentuated
in patients taking ?-blockers and in inadequate planes of anaesthesia.
The reflex vagal stimulation is treated by interrupting the insufflations
of CO2, intravenous atropine administration and by deepening the plane
of anaesthesia after normalization of heart rate.
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Cardiac arrhythmias most often occur during the early stages of
insufflations, when the hemodynamic disturbances due to CO2
insufflation are the most profound. In patients with latent cardiac
disease, arrhythmias also suggest an intolerance to these hemodynamic
changes .Gas embolism is another cause for cardiac arrhythmias.
(v) IMPLICATIONS OF PATIENT POSITIONING DURING
LAPAROSCOPY
Patient positioning is determined by the site of surgery. Pelvic
and lower abdominal surgeries are performed with a head down tilt.
Head up tilt is preferred for upper abdominal surgeries. These variations
in patient positions contribute to various pathophysiological changes
that occur during laparoscopy.
Cardiovascular Effects
Trendelenberg position results in increased central venous
pressure and cardiac output. Baroreceptor reflex response activation
leads to systemic vasodilatation and bradycardia .General anaesthesia
usually attenuates these reflex responses in hemodynamics, and the
hemodynamic alterations induced by laparoscopy in this position are
usually not significant in normotensive subjects24. But these alterations
are accentuated in patients with ischemic heart disease leading to
increased myocardial oxygen demand. Trendelenberg position also
17
causes raised intracranial pressures in cases of decreased intracranial
compliance. Head-down position increases intravascular pressures in the
upper torso, decreases blood pressures in the lower abdominal and
pelvic viscera, thereby decreasing the blood loss due to decreased
transmural pressures but increasing the risk of gas embolism25.
Head up position leads to decreased cardiac output and mean
arterial pressures, due to decreased venous return26.
Lithotomy position leads to accentuation of the venous stasis that
occurs in the head up position.
Respiratory Changes
Head down position leads to a decrease in functional residual
capacity, total lung volumes and pulmonary compliance as well as
causes basal atelectasis. These changes are accentuated in obese and
elderly patients. Head up position is considered to be a more favourable
position for respiratory mechanics.
Nerve Injury
Nerve compression is a common complication occurring in all
positions. Arm should not be abducted beyond 90 degrees. While
placing shoulder braces for head down position, great caution must be
exercised so that the brace does not impinge on the brachial plexus.
Lithotomy position results in injury to the common peroneal nerve and
18
should be protected .Laparoscopic surgeries for prolonged periods in
lithotomy position may result in lower limb compartment syndromes.
(vi) BENEFITS AND CONSEQUENCES OF LAPAROSCOPIC
CHOLECYSTECTOMY
Multiple intraoperative derangements caused by
pneumoperitoneum are counterbalanced by postoperative benefits
including more rapid recovery, heightened feeling of well – being and
reduced postoperative fatigue.
(a) Stress Response
Laparoscopic approach to cholecystectomy results in attenuation
of acute phase reaction, leading to reduced levels of c – reactive protein
(CRP) and interleukin -6 (IL-6) when compared to open technique27.
Laparoscopic technique also results in a decreased metabolic response
(hyperglycaemia, leukocytosis), hence leading to an improved immune
function and nitrogen balance28. Prolonged exposure and manipulation
of intestines and peritoneal incision and trauma are avoided by
laparoscopic approach to cholecystectomy, thereby reducing
postoperative ileus and fasting, duration of intravenous infusion and
hospital stay29.
Endocrine response to surgery does not differ significantly
between laparoscopic and open techniques for cholecystectomy ,
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resulting in similar levels of plasma and urinary concentrations of
catecholamines and their metabolites in both the techniques30.Peritoneal
stretching leading to pain and discomfort, hemodynamic alterations and
ventilator changes caused by CO2 insufflation may contribute to the
stress response induced by laparoscopy, which can be reduced by
perioperative administration of ?2 agonists31.
(b) Postoperative Pain
Pain intensity may be significant after laparoscopic surgeries,
with patients complaining of both visceral and parietal pain. Pain after
laparoscopy is multifactorial and treated by various methods.
Intraperitoneal local anaesthetics are beneficial especially after
gynaecological laparoscopic surgeries. CO2 should be carefully
evacuated, as residual CO2 pneumoperitoneum contributes to
postoperative pain31. Preoperative NSAIDs, dexamethasone and opioid
administration have all contributed to decreased pain intensity after
laparoscopic surgeries. Multimodal analgesia should be provided to
attenuate laparoscopy induced pain.
(c)  Postoperative Pulmonary Dysfunction
Respiratory dysfunction following laparoscopic approach to
cholecystectomy is less severe than after open technique, but however a
slight impairment of diaphragmatic function occurs32. Respiratory
20
dysfunction is greater in obese, elderly, smokers and patients with
COPD.
(d) Postoperative Nausea And Vomiting
 Postoperative nausea and vomiting is one of the complications
that can delay the discharge of patients after laparoscopic surgeries.
Intravenous drainage of gastric contents, administration of droperidol,
5-hydroxytryptamine and liberal intravenous fluid therapy can decrease
the symptoms of nausea and vomiting.
Complications Of Laparoscopic Cholecystectomy
The overall mortality rate is 0.1 to 1 per 1000 cases. Bowel
perforation, common bile duct injury and significant haemorrhage are
some of the major complications. Large vessel injury causing
retroperitoneal hematoma can result in significant bleeding without
intraperitoneal effusion. Anaesthesiologist must be aware of the
occurrence of these complications, and their timely management is vital.
DISTRIBUTION AND PHYSIOLOGICAL RESPONSES
MEDIATED THROUGH ?2 –ADRENOCEPTORS
Adrenoceptors are membrane bound receptors that mediate the
responses of catecholamines, adrenaline and noradrenaline33. In 1948,
Ahlquist classified them into two distinct classes: alpha (?) and beta (?)
34. Alpha adrenoceptors were further divided into ?1 and  ?2 based  on
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their anatomical location .The post synaptic ? adrenoceptor which
mediated responses in the effector organ was designated as ?1 and the
presynaptic ? adrenoceptor which regulated the release of noradrenaline
was designated as ?235.  ?2 adrenoceptors are widely distributed
throughout the CNS and peripheral tissues and they control the
modulation of sympathetic nervous system . ?2 adrenoceptors include
three highly homologous subtypes ?2A, ?2B and ?2C , which are required
for normal regulation of presynaptic neurotransmitter release from
sympathetic nerves in the heart and from the central noradrenergic
neurons36.
??2 adrenoceptors are G-protein coupled receptors that modulate
cellular activity through a second messenger signalling or ion channel
modulation activity .Activation of ?2 adrenoceptors coupled to Gi and Go
proteins results in the inhibition of adenylyl cyclise and subsequent
decrease in 3’ 5’ –cyclic adenosine monophosphate (cAMP) formation.
This reduces protein kinase activity resulting in reduced
phosphorylation of regulatory proteins. Stimulation of phospholipase A2
activity , Na+/  K+ exchange and arachidonic acid metabolism are other
second messenger systems associated .At high concentrations of ?2
agonists , ?2 adrenoceptors couple with stimulatory Gs proteins resulting
in increased adenylyl cyclase activity and increased intracellular Ca2+ ,
which could probably be the reason for smooth muscle contracting
effects of ?2 agonists37. Activation of G-protein gated K+ channels
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produces cell membrane hyperpolarisation, leading to a reduction firing
rate of excitable cells and inhibition of neurotransmitter release. G-
protein coupled ?2 adrenoceptor activation also leads to a decrease in
Ca2+ conductance through direct regulation of voltage gated Ca2+ ion
channels that results in decreased neurotransmitter release from the
nerve terminal38.
 In the CNS, the ?2A and  ?2C receptor subtypes predominate,
whereas in the periphery the predominant subtypes are ?2A and ?2B. The
locus ceruleus of the brainstem, an area important in regulating
vigilance, attention and stress response, has high density of ?2 receptors;
which  contributes  to  the  hypnotic  and  sedative  effects  of  ?2 agonists.
The dorsal motor nucleus of vagus nerve also has a high density of ?2
adrenoceptors and this may have a crucial role in the centrally mediated
cardiovascular effects associated with ?2 adrenoceptor activation. High
densities  of  ?2 adrenoceptors in areas such as the nucleus tractus
solitarius, parts of the ventrolateral medulla and the raphe pallidus may
also contribute to cardiovascular changes. The substantia gelatinosa and
the intermediolateral cell column in the spinal cord also have ?2 agonist
binding sites, responsible for the analgesic effects. The ?2 adrenoceptor
in the vascular beds are responsible for vasoconstriction39.
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Figure 4:  Location and physiological responses mediated through
?2 adrenergic receptors
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LOCATIONS AND PHYSIOLOGIC RESPONSES MEDIATED
THROUGH ?2 ADRENERGIC RECEPTORS40
Location of ?2
Receptors
Response mediated through ?2 Receptors
Central nervous
system
Inhibition of neurotransmitter release leading to
decreased neuronal firing causing bradycardia,
hypotension,sedation,sleep and analgesia
Vascular Smooth muscle contraction by direct action leading
to vasoconstriction
Vasodilatation due to central sympatholysis
Platelet aggregation
Gastrointestinal
tract
Decreases salivation, intestinal secretion and bowel
motility
Pancreas Decreases insulin release
Hypothalamus Increases growth hormone release
Adipose tissue Inhibits lipolysis
Kidney Inhibits renin release
Increases glomerular filtration
Increases secretion of Na+ and H20
Eye Decreases intraocular pressure
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Figure 5: The different physiologic functions of ?2 adrenoreceptors
The top panel depicts the three ?2 receptor subtypes acting as presynaptic
inhibitory feedback receptors to control the release of norepinephrine and
epinephrine from peripheral or central adult neurons. Also, a negative
feedback loop has been seen in the adrenal gland. Alpha2B receptors have
been involved in the development of the placental vascular system during
prenatal development. The lower panel lists a series of physiologic effects
with its associated ?2 adrenoreceptors.
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DEXMEDETOMIDINE
Dexmedetomidine is an ?2 adrenergic agonist which produces
sedation, anxiolysis, hypnosis, analgesia, and sympatholysis.
Dexmedetomidine is a highly selective ?2 agonist  with  1600  times
greater selectivity for the ?2 receptor compared with the ?1 receptor.
Physicochemical Characteristics
 Dexmedetomidine is a d-enantiomer of medetomidine, belonging
to the imidazole subclass of ?2 receptor agonists. It is highly water
soluble. It has a high specificity for ?2 receptor (?2??1 1600:1), when
compared to clonidine (?2??1 200:1).
Pharmacokinetics
  Dexmedetomidine, the dextroisomer of medetomidine, is short
acting with linear concentration dependent kinetics.
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(i) DOSING AND ADMINISTRATION
Desirable pharmacodynamic effects are observed at a plasma
concentration of 0.5-1.2 ng/ml. The dosing regimen approved by FDA
in 1999 is a loading dose of 1 µg/kg administered over a period of 10
minutes followed by continuous intravenous infusion at a rate of 0.2-
0.7µg/kg/hr. The rate of intravenous infusion should be titrated
according to the desired level of sedation. The FDA approved duration
of infusion is 24 hours for ICU sedation. Dexmedetomidine when
administered for less invasive procedures such as ophthalmic surgeries,
is given at a loading dose of 0.5 µg/kg over 10 minutes followed by a
maintenance infusion which is started at 0.6 µg/kg/hr and titrated to
achieve desired clinical41.
(ii) DISTRIBUTION
The pharmacokinetics of Dexmedetomidine is commonly
described using a two-compartment model .It is rapidly distributed after
administration with a distribution half life of 6 minutes. The terminal
elimination half life is approximately 2 – 2.5 hours. The steady state
volume of distribution is approximately 68 L to 72 L. Dexmedetomidine
is highly bound to plasma proteins (94%) without significant variations
in pharmacokinetic parameters between males and females42.
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(iii) METABOLISM AND ELIMINATION
Dexmedetomidine is extensively metabolised in the liver through
glucuronide conjugation and biotransformation by the cytochrome P450
system without formation of toxic metabolites. The resulting methyl and
glucuronide conjugates are excreted by the kidneys. Dexmedetomidine
is metabolised by various metabolic pathways. Direct N-glucuronidation
to inactive metabolites accounts for 41% of metabolism of
Dexmedetomidine. N-methylation to produce 3-hydroxy N-methyl-
Dexmedetomidine is the next major pathway accounting for 21% of
metabolism of Dexmedetomidine. Hydroxylation followed by
conjugation is the other metabolic pathway of Dexmedetomidine. It
undergoes conjugation (41%), n-methylation (21%), or hydroxylation
followed by conjugation42, 43.
The terminal elimination half life of Dexmedetomidine is 2 hours.
The average clearance value for Dexmedetomidine is approximately 45
L/hr in adults. Renal and hepatic diseases greatly impair the
pharmacokinetic properties of Dexmedetomidine. Hepatic impairment
results in an increase in the volume of distribution and half-life of
Dexmedetomidine as well as a decrease in clearance and protein
binding. Renal dysfunction leads to a decrease in the elimination half-
life, however the volume of distribution and clearance are not affected44.
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Molecular Weight 236.7 Daltons
Lipid solubility 30
Distribution t1/2 6 min
Protein Binding 94%
Volume of distribution 118 L
 Elimination t1/2 120-180 min
Context sensitive half time 4 – 250 min
Pharmacodynamics
(i) MECHANISM OF ACTION
The mechanism of action is unique and different from currently
administered sedative agents. Dexmedetomidine acts by activation of ?2
adrenoceptors located in the presynaptic terminal and inhibits the release
of norepinephrine. Activation of ?2 adrenoceptors located in the post
synaptic terminal in the CNS inhibits sympathetic activity and can cause
sedation, anxiolysis along with reduced blood pressure and heart rate. ?2
receptors inhibit adenylyl cyclase activity and result in decreased
intracellular cyclic adenosine monophosphate(cAMP) levels. This
inhibition of adenylyl cyclise activity is transduced by the inhibitory
regulatory protein Gi.
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(ii) EFFECTS ON THE CENTRAL NERVOUS SYSTEM
The pivotal neuroanatomic locus for the sedative – hypnotic
actions  of  ?2  agonists  is  the  locus  ceruleus  (LC)  of  the  brain.
Hyperpolarisation of noradrenergic LC neurons also occurs in Non-
Rapid Eye Movement (NREM) sleep, which involves distinct neuronal
pathways .Thus Dexmedetomidine appears to act by activation of
NREM sleep .Dexmedetomidine exerts a sedative – hypnotic effect by
its  action  on  ?2 receptors in the locus ceruleus and analgesic action by
action on ?2 receptors within the locus ceruleus and spinal cord.
The quality of sedation produced by Dexmedetomidine is unique
in that, patients are easy to wake up and can follow commands while
being tracheally intubated45.  The  ?2 agonists’ actions are readily
reversed by ?2 adrenergic antagonists (e.g.atipemazole) 46. It has recently
been suggested that ?2 agonists produce sedation through endogenous
sleep promoting pathways. Dexmedetomidine reduces the activity of
projections of the locus ceruleus (LC) to the ventrolateral preoptic
nucleus (VLPO); resulting in an increase in the GABAergic and galanin
release in the tuberomammillary nucleus, producing a decrease in
histamine release in cortical and subcortical projections.
Dexmedetomidine also inhibits ion conductance through L-type or P-
type calcium channels and facilitates conductance through voltage gated
calcium-activated potassium channels. Dexmedetomidine maintains the
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cognitive and immunological function in the sleep deprived states, as in
the intensive care unit (ICU) as the hypnosis induced resembles NREM
sleep.
Dexmedetomidine is also reported for use in opioid
detoxification, cocaine withdrawal, benzodiazepine and opioid tolerance
after prolonged sedation. Dexmedetomidine in animal models has CNS
protective effects through reduced intracerebral catecholamine outflow,
modulation of proapoptotic and antiapototic proteins and the reduced
release of excitatory neurotransmitter, glutamate during injury47, 48, 49.
However, CNS protective effects in humans have not been well
documented.
Figure 6:  Dexmedetomidine has been shown to induce a non–rapid
eye movement sleeping pattern (NREM).
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The stimulation of the locus caeruleus (LC) by dexmedetomidine (right
diagram) releases the inhibition the LC has over the ventrolateral
preoptic nucleus (VLPO). The VLPO subsequently releases gamma
aminobutyric acid (GABA) onto the tuberomammillary nucleus (TMN).
This inhibits the release of the histamine on the cortex and forebrain
which prevents arousal and induces the loss of consciousness.
(iii) ANALGESIA
Dexmedetomidine has complex analgesic effects. There are two
predominant mechanisms to achieve analgesia namely, activation of
descending spinal inhibition and direct activation of presynaptic ?2
receptors on sensory afferent terminals in the dorsal horn. One of the
major descending analgesic systems in the CNS utilizes a noradrenergic
system that originates in the brainstem locus ceruleus (LC) and
terminates on the dorsal horn of spinal cord.
The  binding  of  ?2 agonists in the LC results in norepinephrine
release from its descending inhibitory track onto presynaptic terminals
of C and A? type primary afferent neurons. The subsequent activation of
presynaptic ?2 rectors by norepinephrine in the dorsal horn reduces
evoked release of excitatory amino acids and neuropeptides from
nociceptive neurons, resulting in an analgesic effect. Another property
possessed by systemic administration of Dexmedetomidine is its
narcotic sparing effects.
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Analgesic effects are principally mediated through ?2 receptors
when the drug is injected via intrathecal or epidural route50. The
analgesic effects of ?2 adrenergic agonists and opioids are mediated by
different routes, and hence produce a synergistic analgesic action
without increasing the incidence of respiratory depression. This, opioid
sparing effect is associated with decreased incidence of side effects such
as nausea, vomiting and respiratory depression. Systemic ?2 adrenergic
agonists may be administered as a perioperative supplement to improve
loco regional analgesia. Perioperative Dexmedetomidine also increases
the duration of local anaesthetic action in spinal or peripheral nerve
block51, 52. Some of the systemic analgesic effects of Dexmedetomidine
are attributed to the confounding sedative effects. The analgesic-sparing
effect observed after a perioperative administration usually lasts up to
24 hours, with the anxiolytic, sedative, and thymoanaleptic properties
implicated as being partly responsible for this effect53, 54.
(iv) EFFECTS ON RESPIRATORY SYSTEM
Sedation producing concentrations of Dexmedetomidine produce
a decrease in minute ventilation, but the ventilator responses of CO2 are
retained55. Higher concentrations produce a 20 % increase in PaCO2.
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(v) EFFECTS ON CARDIOVASCULAR SYSTEM
?2 agonists are characterized by varied effects on the
cardiovascular system including decreased heart rate and systemic
vascular resistance and indirectly decreased myocardial contractility,
cardiac  output,  and  systemic  blood  pressure.  Bolus  dose  of
Dexmedetomidine results in a biphasic hemodynamic response,
producing an initial increase in blood pressure due to direct stimulation
of peripheral ?2 receptors and a decrease in heart rate. The heart rate
returns to baseline in 15 minutes and the blood pressure reduces to about
15% of baseline values in about 60 minutes. Administration of loading
dose leads to increased incidence of hypotension and bradycardia, which
can be avoided by omitting the loading dose, or reducing the loading
dose to 0.4µg/kg, or administering the loading dose slowly over 20
minutes .Centrally, ?2 agonist administration reduces blood pressure by
attenuating sympathetic nervous system tone through a decrease in both
spontaneous and evoked sympathetic activity. Stimulation of central
postsynaptic ?2 adrenoceptors result in the inhibition of sympathetic
outflow and the subsequent decreases in plasma catecholamine
concentrations through action at the regulatory centres in the brainstem
such as locus ceruleus and nucleus tractus solitarius. Activation of
presynaptic ?2 receptors reduces the release of catecholamines from the
neuroeffector junction. The decrease in blood pressure corresponds to
decrease in plasma catecholamine concentrations. At the same time, ?2
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adrenoceptors in the periphery cause vasoconstriction leading to
increased systemic vascular resistance .The overall effect on blood
pressure is the sum of these two opposing effects.
Dexmedetomidine exhibits no direct depressant effects on the
contractile properties of isolated myocardium. In animal models
Dexmedetomidine showed some beneficial effects on the ischemic heart
through decreased oxygen consumption and redistribution of coronary
flow from nonischemic zones to ischemic zones after acute brief
occlusion. The perioperative use of ?2 agonists reduces the incidence of
perioperative myocardial ischemia. Overall a reduction in myocardial
oxygen demand and a decrease in coronary perfusion pressure results as
a consequence of hypotension. On balance myocardial energetic are
usually improved; however in some patients hypotension may produce
myocardial ischemia56.
Depression of both spontaneous and evoked sympathetic activity
in the vasomotor centre of the brainstem occurs at therapeutic doses of ?
adrenergic agonists, given by oral, intravenous (slowly) or epidural
routes of administration .Hence sympatholysis is the predominant
hemodynamic effect. Stimulation of ?2B adrenoceptors in the peripheral
vasculature produces peripheral vasoconstriction. Unlike clonidine, no
rebound hypertension has been found with the discontinuation of
Dexmedetomidine infusion even when it is given for more than 24
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hours. As clinically used ?2 adrenergic agonists possess an imidazoline
structure, some of the hemodynamic effects that are observed may be
produced by the imidazoline I1 receptors in the rostral ventrolateral
medulla. Hence hypotension induced by ?2 adrenergic agonists cannot
be  completely  reversed  by  the  ?2 adrenergic antagonist Yohimbine,
which has a non imidazoline structure but by vasopressors and
inotropes. There appears to be an enhanced pressor response to
Ephedrine, Phenylephrine and Dobutamine, but not to Norepinephrine57.
The effects of ?2 adrenergic agonists are readily reversible by the ?2
adrenergic antagonist Atipemazole.
Uses
(i) INTENSIVE CARE UNIT
Dexmedetomidine has been approved for sedation in
mechanically ventilated patients and lesser amounts of opioids are
required, when Dexmedetomidine is used for sedation compared to
propofol or benzodiazepines. It produces unique characteristics of
sedation with minimal respiratory depression. Also, Dexmedetomidine
when used for sedation provides a more stable hemodynamics during
weaning58.Dexmedetomidine is used for the treatment of withdrawal of
narcotics, benzodiazepines, alcohol, and recreational drugs59.
37
(ii) ANAESTHESIA
Dexmedetomidine has been used as a premedicant in doses of 0.3
- 0.6 µg/kg , reducing the requirements of intravenous and volatile
anaesthetics and also attenuating the hemodynamic stress response to
endotracheal intubation 60,61.Dexmedetomidine is also used for sedation
in patients for monitored anaesthesia care .When used as a
premedication for cataract surgeries , intraocular pressure decreases,
catecholamine secretion decreases and also perioperative analgesic
requirements are lesser, recovery rates are rapid . For maintenance of
anaesthesia, Dexmedetomidine is used in infusion rates of 0.2-0.7
µg/kg/hr. This reduces postoperative pain scores, morphine
consumption and improved hemodynamics when compared with
desflurane - fentanyl or propofol – fentanyl anaesthetics62, 63.
This highly selective ?2 agonist has unique characteristics that
include titrable sedation, sympatholysis and analgesia without
significant respiratory depression, which has led to a dramatic increase
in its use in many off – label applications in the ICU, operating room,
and perioperative environment.
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CHAPTER 3
REVIEW OF LITERATURE
Aantaa R et al64 (Anaesthesiology 1997) conducted a study to
determine the effects of Dexmedetomidine on the minimal alveolar
concentration (MAC) of isoflurane. MAC of isoflurane was chosen as
the measure of anaesthetic potency in his study. The study was
conducted on 49 women posted for abdominal hysterectomy. Patients
were randomized into two groups. The patients in the first group
received placebo infusion. A two-stage infusion of Dexmedetomidine
was used in the second group with a target plasma concentration of 0.3
ng/ml or 0.6 ng/ml. Dexmedetomidine infusion was started 15 minutes
before the induction of anaesthesia and was continued until skin closure.
Induction of anaesthesia was performed with thiopental and alfentanil.
Up-down method of Dixon was used to predetermine the end tidal
concentration of isoflurane. This end-tidal concentration was maintained
for  15  minutes  and  then  the  patient’s  response  to  skin  incision  was
assessed. In the control group the MAC of isoflurane was 0.85% end-
tidal. In the Dexmedetomidine 0.3 ng/ml group the MAC was 0.55%
end-tidal and in the Dexmedetomidine 0.6 ng/ml group the MAC was
0.45% end-tidal. His study concluded that MAC of isoflurane was
significantly lesser in the Dexmedetomidine group when compared to
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the control group and also showed that increasing plasma concentrations
of Dexmedetomidine resulted in progressive decreases in MAC of
isoflurane.
Ebert Thomas et al65 (Anaesthesiology 2000) conducted a study
to evaluate the effects of increasing plasma concentrations of
Dexmedetomidine. The study was conducted on 10 healthy volunteers.
The following monitors were used- ECG, pulse oximetry, EtCO2,
invasive blood pressure, central venous pressure, pulmonary artery
pressure, cardiac output, respiratory rate, arterial blood gases and
plasma catecholamine concentrations. During the study specific tests
were performed at every 40 minute intervals during the sequential
increase in Dexmedetomidine plasma concentrations (0.5, 0.8, 1.2, 2.0,
3.2, 5.0, and 8.0 ng/ml; baroreflex testing only at 0.5 and 0.8 ng/ml).
Hemodynamic parameters and blood gases were observed.
Psychometric tests, cold pressor and baroreflex tests were performed.
He observed the following results. Plasma catecholamine concentrations
were decreased at all doses of Dexmedetomidine. Dexmedetomidine in
plasma concentrations of 0.5 ng/ml and 0.8 ng/ml increased sedation by
38% & 45% respectively and reduced mean arterial pressure by 13%.
Central venous pressure and pulmonary arterial pressure remained
unchanged. Progressive increase in plasma concentrations of
Dexmedetomidine resulted in progressively increasing sedation,
progressive increase in all pressures and systemic vascular resistance
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and progressive decrease in heart rate, cardiac output and stroke volume.
Progressive increase in plasma concentrations of Dexmedetomidine also
resulted in progressively decreasing pain rating scores. Increase in MAP
to cold pressor test progressively diminished as the plasma
concentrations of Dexmedetomidine diminished. This study concluded
that increasing concentration of Dexmedetomidine results in
progressively increasing analgesia and sedation, and progressive
decreases in heart rate, cardiac output, memory and attenuation of cold
pressor response.
Aho et al66 (Anesthesiology 1991) conducted a study to evaluate
the effects of Dexmedetomidine on maintaining hemodynamic stability
during the perioperative period and to analyze its effects on isoflurane
requirements in patients undergoing abdominal hysterectomy. The study
was conducted on 96 women undergoing abdominal hysterectomy,
randomized into four groups receiving Dexmedetomidine 0.3 µg/kg,
Dexmedetomidine 0.6 µg/kg, fentanyl 2.0 µg/kg, or saline respectively.
All the above drugs are administered as a single bolus dose 10 minutes
prior to the induction of anaesthesia. Induction was performed with
thiopental 4.0 mg/kg. Maintenance of anaesthesia was initiated with
Isoflurane 0.3% end-tidal concentration in 70% nitrous oxide. Blood
pressures and heart rate were maintained within 20% of baseline values
by varying the end-tidal isoflurane concentration. Fentanyl was
supplemented if the end-tidal isoflurane concentration exceeded 1.5%.
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Increase in blood pressure and heart rate was recorded in all the four
groups on tracheal intubation. But the degree of increase was lesser in
Dexmedetomidine 0.6 µg/kg group when compared to the saline group
(P<0.01). Heart rate response to endotracheal intubation was
significantly lesser in Dexmedetomidine group when compared to the
saline or fentanyl group. The end-tidal isoflurane concentration required
was also significantly less in the Dexmedetomidine group (0.35%) when
compared to the saline (0.47%) or fentanyl (0.48%) groups. This study
concluded that Dexmedetomidine when administered as a single bolus
dose prior to induction resulted in significant attenuation of the stress
response to endotracheal intubation and also greatly diminished
isoflurane requirements when compared to fentanyl.
Feld et al67 ( J Clin Anesth 2006 ) conducted a study to determine
whether Dexmedetomidine could serve as a better alternative to fentanyl
for analgesia in patients undergoing bariatric surgery . The study was
conducted on 20 patients with an average BMI of 54 to 61 kg/m2
undergoing gastric bypass surgery. The patients were randomly
allocated into two groups. First group received fentanyl bolus of 0.5
µg/kg followed by an infusion at a rate of 0.5 µg/kg/hr. The second
group received Dexmedetomidine at a bolus dose of 0.5 µg/kg followed
by infusion at a rate of 0.4 µg/kg/hr. In the study bispectral index was
maintained at 45-50 by varying end-tidal desflurane concentration.
Heart rate and blood pressure were recorded every 5 minutes
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intraoperatively. End-tidal desflurane concentration and bispectral index
were observed every 60 minutes. Post-operative pain scores and
morphine consumption by patient controlled analgesia devices were also
determined. Mean blood pressure and heart rate and the average end-
tidal desflurane concentration were significantly reduced in
Dexmedetomidine group when compared to the fentanyl group. Post-
operative pain scores and morphine consumption were also decreased in
the Dexmedetomidine group. The study concluded that
Dexmedetomidine attenuated blood pressure and provides post-
operative analgesia, when used as a substitute to fentanyl during gastric
bypass surgery.
Hall et al68 ( Anesth Analg 2000) conducted a study to evaluate
the efficacy of two small infusion doses of Dexmedetomidine. They
studied the effects of Dexmedetomidine on sedation, analgesia,
cognition and respiratory function. The study was conducted on seven
healthy volunteers. Informed consent was obtained. The study was
conducted in three phases. The participants were randomly assigned to
receive two different doses of drug or placebo. The following monitors
were used- heart rate, NIBP, respiratory rate, EtCO2, SpO2 and EEG
(bispectral analysis). Baseline hemodynamic parameters were recorded.
Various psychometric tests were performed including visual analog
scale for sedation, alertness scale, memory and digit symbol substitution
test. Cold-pressor test was used to quantify pain. All patients received a
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10 minute infusion dose of saline or Dexmedetomidine at a dose of 0.2
or 0.6 µg/kg/hr. All patients were again evaluated at the end of drug
infusion and also during the recovery period. Dexmedetomidine infusion
resulted in significant sedation and impairment of memory and
psychomotor performance with preservation of heart rate, blood
pressure, SpO2, EtCO2 and respiratory rate. Pain response to cold
pressor test was also suppressed. The study thus concluded that small
intravenous doses of Dexmedetomidine provided reversible sedation,
analgesia, memory and cognitive impairment without any
cardiorespiratory compromise.
Aho et al69 ( Anesth Analg 1992 )conducted a study to determine
the efficacy of Dexmedetomidine when used as an intravenous infusion
for the maintenance of anaesthesia. Patients were anesthetised with
thiopental, fentanyl and isoflurane. It was decided to conduct the study
in two phases. The first phase was conducted on 14 women undergoing
abdominal hysterectomy and it was a dose response study. In this phase
the dosing of Dexmedetomidine was determined from the measured
hemodynamic parameters. The second phase of the study was then
conducted on 20 patients randomized into two groups. One group
received placebo and the other group received Dexmedetomidine
infusion. Dexmedetomidine was administered as a two staged infusion.
The initial dose was administered over 10 minutes prior to the induction
of anaesthesia. The maintenance rate was commenced from the time of
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induction and was continued till the closure of abdominal fascia.
Dexmedetomidine dose ranges in the dose response phase varied from
120 ng/kg/min to 270 ng/kg/min. They chose an initial infusion dose of
170 ng/kg/min for the second phase of the study followed by 10
ng/kg/min for maintenance. During surgery isoflurane was titrated
according to predetermined hemodynamic criteria. Dexmedetomidine
infusion decreased the requirement of isoflurane by >90%. The
endocrine stress response to endotracheal intubation was also blunted.
Their study thus concluded that Dexmedetomidine decreased the
requirement of isoflurane and also blunted the stress response to
endotracheal intubation.
Talke et al70 (Anesth Analg 1997) designed a study to determine
the postoperative pharmacokinetic and sympatholytic effects of
Dexmedetomidine. The study was conducted on 8 women.
Dexmedetomidine was infused for 60 minutes postoperatively by
computer-controlled infusion protocol (CCIP) with a target plasma
concentration of 600 pg/ml. Blood sampling was done thrice – before
the start of infusion, during and after the infusion and plasma levels of
norepinephrine, epinephrine and Dexmedetomidine were also
determined. Norepinephrine levels decreased from 2.1 +/- 0.8 to 0.7 +/-
0.3 nmol/L; epinephrine decreased from 0.7 +/- 0.5 to 0.2 +/- 0.2
nmol/L. There was also a significant decrease in the heart rate and
systolic blood pressure. The study thus concluded that
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Dexmedetomidine attenuates sympathetic activity during the
intraoperative and immediate postoperative period.
Arain  SR  et  al71 (Anesth Analg 2002) designed a comparative
study to evaluate the efficacy, adverse effects and recovery
characteristics of Dexmedetomidine and propofol. Cardiorespiratory
effects were also evaluated. Sedation, postoperative analgesia and
psychomotor performance were chosen as secondary end points. The
study was conducted on 40 patients randomized into 2 groups. The first
group received Dexmedetomidine at a loading dose of 1 µg/kg
administered over 10 minutes followed by an infusion dose of 0.4-0.7
µg/kg/min. The second group received propofol – loading dose of 75
µg/kg/min over 10 minutes followed by a maintenance dose of 12.5-75
µg/kg/min. Heart rate and mean blood pressure were studied every 5
minutes. Sedation was assessed with visual analogue scale and Observer
Assessment of Alertness scale. Respiratory rate, SpO2, EtCO2 were also
monitored. Psychomotor performance was analyzed using digital
symbol substitution test. Pain was assessed using visual analogue scale.
Intraoperative sedation levels were targeted to maintain a bispectral
index score of 70-80. Sedation was achieved more rapidly with propofol
when compared to Dexmedetomidine.The average infusion rate was 0.7
µg/kg/hr for Dexmedetomidine and 38 µg/kg/min for propofol.
Psychomotor performance and respiratory rate showed no difference
between two groups. The study concluded that Dexmedetomidine causes
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more sedation, results in lower blood pressure and improved analgesia
when compared to propofol.
Alp  Gurbet  et  al72 (Can  J  ANESTH  2006)  designed  a  study  to
evaluate the efficacy of Dexmedetomidine in providing post operative
analgesia. Post operative pain scores and morphine consumption were
studied. The study was conducted on 50 women posted for total
abdominal hysterectomy. The patients were randomly assigned into two
groups. The first group received Dexmedetomidine at a loading dose of
1 µg/kg followed by maintenance at a rate of 0.5 µg/kg/hr. The second
group received placebo infusion. Heart rate SpO2, systolic and diastolic
blood pressures were monitored. Morphine was administered post
operatively by patient controlled analgesia device. Pain and sedation
scores and total morphine consumption were studied for 48 hours
following surgery. Pain and sedation scores between the two groups
were similar. Patients in the Dexmedetomidine group required
significantly less morphine when compared to the placebo group. The
study thus concludes that Dexmedetomidine provides effective post
operative analgesia, and reduces morphine consumption post operatively
without increasing the incidence of adverse effects.
Talke et al73 (Anaesthesiology 1995) studied the perioperative
effects of Dexmedetomidine in patients undergoing vascular surgery.
The study was conducted on 24 patients undergoing vascular surgery.
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Patients were randomized into four groups. The first group received
placebo. The second group received low dose Dexmedetomidine (0.15
ng/ml). The third group received medium dose Dexmedetomidine (0.30
ng/ml). The fourth group received high dose Dexmedetomidine (0.45
ng/ml). The infusion was started 60 minutes prior to induction and was
continued till 48 hours post operatively. The patients were monitored
with  NIBP,  heart  rate,  SpO2, ECG, anaesthetic concentrations,
intraoperative ECHO. Post operative cardiac enzymes were also studied.
There was a progressive decrease in heart rate and systolic blood
pressure as the dose of Dexmedetomidine progressively increased. Post
operatively Dexmedetomidine groups had less tachycardia when
compared to the placebo group. Also intraoperatively patients in the
Dexmedetomidine groups required more vasoactive interventions to
maintain the hemodynamic parameters within the desired range. This
study showed that Dexmedetomidine upto a plasma concentration of
0.45 ng/ml has a beneficial effect on perioperative hemodynamic
management, but requires more pharmacological interventions to
maintain blood pressure and heart rate within the desired limits.
Tufanogullari et al74 (Anaesthesia –Analgesia, 2008) conducted
a  study  to  evaluate  the  effects  of  Dexmedetomidine  on  both  early  and
late recovery. Eighty morbidly obese patients posted for laparoscopic
bariatric surgery were chosen. Informed consent was obtained. The
patients were randomly assigned to 4 groups. The first group received
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saline infusion. Dexmedetomidine 0.2 group received an infusion of 0.2
µg/kg/hr IV. Dexmedetomidine 0.4 group received an infusion of 0.4
µg/kg/hr IV and Dexmedetomidine 0.8 group received an infusion of 0.8
µg/kg/hr. Desflurane concentrations were titrated to maintain mean
arterial pressure values within 25 % of baseline values. Hemodynamic
parameters, postoperative pain scores, and the need for “rescue”
analgesics and antiemetics were studied. Average end-tidal desflurane
concentrations progressively decreased by 19%, 20% and 22% as the
concentration of Dexmedetomidine is progressively increased
respectively. Blood pressures and the length of stay in PACU were
significantly reduced in Dexmedetomidine groups when compared to
the saline group. The need for rescue fentanyl and antiemetic therapy
was also reduced in Dexmedetomidine group when compared to the
saline groups. The study thus concluded that adjunctive administration
of Dexmedetomidine in doses of 0.2-0.8µg/kg/hr decreased fentanyl
use, antiemetic therapy, and the length of stay in the PACU.
Hirvonen  EA  et  al75 (Surgical endoscopy 2000) conducted a
study to determine the effects of patient positioning, anaesthesia and
increased intraabdominal pressure during laparoscopy on cardiac
performance. 15 ASA class I patients posted for laparoscopic
cholecystectomy were chosen. Using invasive monitoring,
hemodynamic changes were investigated. Cardiac index (CI), stroke
index (SI), central venous pressure (CVP), pulmonary capillary wedge
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pressure (PCWP), and systemic vascular resistance were monitored.
Measurements were first taken in the supine position and then in the
head-up position (15-20 degrees) both when awake and after the
induction of anaesthesia. Head-up tilt resulted in decreased cardiac
index (CI), stroke index (SI), central venous pressure (CVP), pulmonary
capillary wedge pressure (PCWP), and increased systemic vascular
resistance. Carbon dioxide insufflation resulted in increases in CVP and
PCWP,  systemic  and  pulmonary  arterial  pressures.  CI  or  SI  remains
unchanged. Deflation of gas results in normalization of these
hemodynamic parameters. The study thus concluded that head – up
positioning accounts for many of the adverse effects in hemodynamics
during laparoscopic cholecystectomy.
Jorris J et al76 (Anesth Analg 1993) conducted a study to
determine the hemodynamics ( invasive arterial pressure , PAP, RAP ,
PCWP  ,  HR  ,CO  ,  SVR  and  pulmonary  vascular  resistance  )  during
laparoscopic cholecystectomy.15 ASA class I patients were chosen.
Intra-abdominal pressure was maintained constant at 14 mmHg.
Hemodynamics measurements were made preoperatively, after the
induction of anaesthesia, head up tilt, 5, 15 and 30 minutes after
peritoneal insufflation, and 30 minutes after exsufflation . Head-up tilt
resulted in a significant reduction in cardiac preload and caused further
reduction of CI. Peritoneal insufflations caused a significant increase of
mean arterial pressures (35%), a significant reduction of CI (20%), and a
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significant increase of systemic (65%) and pulmonary (90%) vascular
resistances. The combined effect of anaesthesia, head-up tilt, peritoneal
insufflations produced a 50% decrease in CI. This study concludes that
laparoscopic cholecystectomy in the head-up position results in
significant hemodynamic changes, mainly at the beginning of peritoneal
insufflation.
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CHAPTER 4
MATERIALS AND METHODS
This study on patients undergoing laparoscopic cholecystectomy
was approved by the Institutional Ethical Committee, Stanley Medical
College, Chennai. This was a prospective study conducted on 60
patients over a period of 1 year. Pre-anaesthetic evaluation was done,
recording a detailed history and performing a complete physical
examination. Complete blood count, renal function test, blood
grouping/typing, random blood sugar, HBsAg, HCV and anti retroviral
screening tests were done. After discussion of anaesthetic options, a
written preoperative consent was obtained.
SAMPLE SIZE AND RANDOMIZATION
The sample size was calculated as 60 based on the pilot study and
statistical reports from previous studies. The group sizes (n =30) were
calculated to detect a reduction in the total fentanyl requirement and /or
average inspiratory desflurane concentrations, with a power of 90%
[assuming a variability (sd) of ±10%] and a significance level of 0.05.
They were randomly allocated to 30 in each group and were named as
Group A (Dexmedetomidine 0.2 µg/kg/hr) and Group B (0.6 µg/kg/hr).
The investigator prepared 60 lots numbered serially from 1-60. A coding
sheet was also simultaneously prepared that allotted each number
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randomly to a group. The observer is allowed to take a lot and the
selected number was marked in the proforma .Then the observer is
blinded for dose of drug being infused and performs the procedure. At
the end of the study coding sheet was revealed. For the serial numbers
which were selected and excluded as per the exclusion criteria, the same
serial number is mixed again in the lot by the investigator.
(i) INCLUSION CRITERIA
(a) ASA grade I
(b) Age 18 to 55 years
(c) Weight 60 ± 20 kg
(d) Both Sex
(e) Undergoing Endotracheal General Anaesthesia
(f) Laparoscopic Cholecystectomy
(g) Without any co morbid illness
(ii) EXCLUSION CRITERIA
(a) Allergy to alpha -2 adrenergic agonist or sulpha drugs
(b) Clinically significant cardiovascular ,neurologic ,renal,
hepatic or gastrointestinal diseases
(c) Pregnant and nursing women
(d) Morbid obesity
(e) Hypertensive patients on beta blockers
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(f) Diabetes
(g) Heart block
(h) History of alcohol or drug abuse
CONDUCT OF ANAESTHESIA
Groups
Group A : Patients receiving desflurane – fentanyl –
Dexmedetomidine infusion at 0.2 µg/kg/hr
Group  B  : Patients receiving desflurane – fentanyl –
Dexmedetomidine infusion at 0.6 µg/kg/hr
Monitoring
Monitors that were made available included
(a) NIBP
(b) SPO2
(c) ECG
(d) ETCO2
(e) HR
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Methodology
60 patients within the age of 18 – 55 years undergoing
laparoscopic cholecystectomy under endotracheal general anaesthesia
were randomized into two groups of 30 each.
All patients were fasted for 8 hours before the planned surgical
procedure. Tab. Ranitidine 150mg, Tab. Metoclopramide 10mg and
Tab. Diazepam 5mg were given orally on the night before surgery and at
6 am on the day of surgery with sips of water. On the day of surgery all
patients were shifted to the premedication room and a peripheral
intravenous line was secured using 18 G IV cannula.
Preparation of Study Medication
Infusion of the study medication was prepared (100 µg of
Dexmedetomidine added to saline to achieve a total volume of 50ml – 2
µg / ml preparation). The weight adjusted doses were based on patients’
actual body weight.
Premedication
All patients were premedicated with Inj. glycopyrrolate 0.2 mg
IM 30 minutes before entering the operating room.
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The patients’ baseline heart rate, BP, SPO2, RR were recorded 5
min  after  arrival  in  the  operating  room.  Patients  SpO2, NIBP, ECG,
ETCO2 and heart rate were monitored.
After obtaining the baseline HR and BP, infusion of the study
medication was started at weight adjusted doses according to the
patients’ actual body weight.
Preoxygenation with 100% oxygen for 3 minutes was started 7
minutes after the commencement of infusion medication.
 Inj. Fentanyl at a dose of 1µg/kg was administered before
induction of anaesthesia.
Induction
Anaesthesia was induced 10 min after the commencement of
study drug infusion with propofol 2 mg / kg IV and muscle relaxation
was obtained by Inj. Atracurium at a dose of 0.5 mg/kg. Desflurane was
administered at an inspiratory concentration of 3%.
Maintanence
Anaesthesia was initially maintained with nitrous oxide (3 l /
min), oxygen (1.5 l /min) mixture with desflurane administered at 3 %
inspired concentrations. Ventilation was adjusted to maintain EtCO2
between 30 and 40 mmHg. Muscle relaxation was achieved by
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administration of Inj. Atracurium in doses of 0.1 mg/kg IV every 20
minutes.
Intra  –operative  HR,  SBP,  DBP,  MAP,  SpO2, EtCO2 were
recorded every 5 min for first 30 min and subsequently every 10 min
intervals till the discontinuation of anaesthetic drugs .Hemodynamic
variables were also recorded at specific end –points (induction of
anaesthesia, 1 min after induction, intubation, 5 min after tracheal
intubation, skin incision, 5 min and 10 min after skin incision).
MAP and heart rate values were maintained within 25% of
baseline values by administering bolus doses of fentanyl at 0.5 µg / kg
(up to a maximum of 2 µg / kg) and by varying inspiratory desflurane
concentrations.
Hypotension (defined as MAP < 25 % of baseline values on two
consecutive readings within 2 – 3 min), was first treated by decreasing
the desflurane concentration and by administering fluid bolus of 200ml.
Hypotension not responding to the above two interventions, was treated
with Inj. Ephedrine in bolus doses of 6 mg IV. The infusion of study
medication was stopped if hypotension persists > 3 min after these
interventions. Upon return of MAP to within 25 % of baseline values the
infusion of study medication was resumed at 50 % of initial infusion
rate and the inspiratory concentration of desflurane was reset at 3%.
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In the presence of hypertension (defined as MAP value > 25 % of
baseline values on two consecutive readings within 2 – 3 min) and / or
tachycardia (defined as HR > 25 % of baseline values > 2 min), bolus
doses of fentanyl at 0.5 ug / kg (up to a maximum of 2 ug / kg) were
administered at 10 min intervals. Hypertension and tachycardia not
responding to fentanyl boluses were treated by increasing the inspiratory
concentrations of desflurane in steps of 1% up to a maximum inspiratory
concentration of 6%. Hypertension and tachycardia not responding to
the above interventions were treated by administration of propofol in
bolus doses of 0.5mg/kg IV.
Bradycardia defined as HR < 50 persisting for > 2 min, was
treated with Inj. Atropine 0.6 mg IV boluses.
During the surgical procedure patients received IV crystalloid
solutions calculated according to the Holliday Segar formula (4-2-1
formula) and IAP was set at a constant value of 12 mm Hg.
Ondansetron 0.1 mg/kg IV was given for the prevention of post
operative nausea and vomiting once the laparoscope is withdrawn.
Infusion of Dexmedetomidine and desflurane administration was
discontinued upon the start of wound closure and inspired oxygen flow
rate increased to 5 l / min.
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After wound closure residual neuromuscular block was reversed
with Inj .neostigmine 0.04 mg / kg IV and glycopyrrolate 0.01 mg / kg
IV, once the patients started breathing spontaneously. When
spontaneous respirations were adequate and patients were able to obey
simple commands, oropharyngeal suctioning was done and tracheal
extubation was performed.
Times from discontinuation of  Dexmedetomidine to eye opening,
and tracheal extubation were recorded.
 The degree of sedation following tracheal extubation was
assessed using the Ramsay sedation scale.  In this system, 1 = agitated
and uncomfortable, 2 = cooperative and orientated, 3 = can follow
simple directions, 4 = asleep but strong response to stimulation,
5  =  asleep  and  slow  response  to  stimulation,  and  6  =  asleep  and  no
response to stimulation.
The average inspiratory desflurane concentrations was calculated
as the sum of the products of inspiratory concentrations and times
divided by the total anaesthesia time.
All patients were shifted to the post anaesthesia care unit at the
end of the surgery and were observed for four hours. Hemodynamic
variables such as heart rate, SBP, DBP, MAP and SpO2 were monitored.
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Sedation scores were studied at 30 minute intervals for two hours and
then every 60 minutes for the subsequent two hours.
Total fentanyl requirement, average inspiratory desflurane
concentrations, HR, SBP, DBP, SPO2, ETCO2, post operative sedation
score and intraoperative requirement for adjuvant such as propofol were
studied.
Parameters Studied
All the parameters and results from two groups (Group A and
Group B) were entered in the predesigned proforma sheet.
i. Total fentanyl requirement throughout the surgical procedure
ii. The average inspiratory desflurane concentrations calculated as
the sum of the products of inspiratory concentrations and times
divided by the total anaesthesia time.
iii. Heart rate (HR), systolic blood pressure (SBP), diastolic blood
pressure (DBP), mean arterial pressure (MAP), oxygen saturation
(SpO2), EtCO2 every 5 minutes for the first 30 minutes and then
subsequently every 10 minutes till the discontinuation of
anaesthetic drugs and also at specific end points( induction, 1
minute after induction, intubation, 1 minute after intubation and
peritoneal insufflation).
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iv. Sedation scores following extubation, 30 minute intervals for the
first two hours following extubation and then at 60 minute
intervals for the next two hours.
v. Intraoperative need for adjuvant such as propofol.
vi. Intraoperative need for a fluid bolus and ephedrine administration.
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CHAPTER 5
OBSERVATION AND RESULTS
After collecting the data, all the variables are examined for
outliers and non-normal distributions. The Categorical variables are
expressed as Frequency and Percentage. The Quantity variables are
expressed as mean and standard deviation. Descriptive statistics are used
to evaluate baseline characteristics.
Student’s t-test was used to analyze the parametric data, and
discrete (categorical) variables were analyzed using the ?2 test, with a P
< 0.05 considered statistically significant.
 The statistical analysis was carried out using statistical software
package SPSS 22.0.
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Table 1:  Comparison of mean of age, weight and mean duration
of surgery between Group A and Group B
GROUP A GROUP B p value
Age 34.07 +10.81 33.50±10.87 0.837
Weight 58.76±6.01 59.20 + 5.997 0.536
Duration of surgery 96.55±22.08 100.00±14.14 0.137
The mean age of patients in Group A and Group B was 34.07
years and 33.50 years respectively.
The  mean  weight  of  patients  in  Group  A  and  Group  B  was
58.76kg and 59.20 kg respectively.
The mean duration of surgery in Group A and Group B was 96.55
minutes and 100 minutes respectively.
On analysing the data statistically, the p value was calculated as
p=0.837, p=0.536 and p=0.137 for age, weight and duration of surgery
respectively. All these values were >0.05, hence the difference was
statistically insignificant between the two groups in terms of age, weight
and duration of surgery, and the two groups were therefore comparable.
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Figure 7: Bar chart comparing Group A and Group B in mean
age, weight and duration of surgery
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Table 2: Comparison of gender distribution between Group A
and Group B
Gender Group A Group B P value
Male 6 7 1.000
Female 24 23 1.000
Total  number  of  males  in  Group  A  and  Group  B  was  6  and  7
respectively.
Total number of females in Group A and Group B was 24 and 23
respectively.
 On analysing the data statistically, the p value was calculated as
p=1.000 for both males and females between the two groups
respectively. All these values were >0.05, hence the difference was
statistically insignificant between the two groups in terms gender
distribution, and the two groups were therefore comparable.
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Table 3: Comparison of mean of total fentanyl requirement and
average inspiratory desflurane concentrations between
Group A and Group B
Group A Group B p value
Total fentanyl 74.31 ± 18.56 60.00 ± 2.99 0.001
Avg. Inspiratory
desflurane 2.66 ± 0.091 2.57 ± 0.12 0.002
The mean of total fentanyl required in Group A and Group B was
74.31 µg and 60.00 µg respectively.
The mean average inspiratory desflurane concentration in Group
A and Group B was 2.66 and 2.57 respectively.
On analysing the data statistically, the p value was calculated as
p=0.001 and p=0.002 for total fentanyl and average inspiratory
desflurane concentrations respectively. All these values were <0.05,
hence the difference was statistically significant between the two groups
in terms of total fentanyl, and average inspiratory desflurane
concentrations. Hence we concluded that total fentanyl requirements and
the average inspiratory desflurane concentrations were significantly
lesser in group B when compared to group A.
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Figure 8:  Bar diagram comparing the mean of total fentanyl and
average inspiratory desflurane concentrations between
Group A and Group B
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Table 4: Comparison of total number of bolus doses of fentanyl
required between Group A and Group B
Group A Group B P value
Number of Fentanyl bolus
doses 16 2 0.001
The total number of bolus doses of fentanyl required in Group A
was 16.
The total number of bolus doses of fentanyl required in Group B
was 2.
On analysing the data statistically, the p value was calculated as
p=0.001 for total number of bolus doses of fentanyl required in Group A
and Group B. All these values were <0.05, hence the difference was
statistically significant. Hence we concluded that the number of bolus
doses of fentanyl required in group A was significantly higher when
compared to group B.
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Figure  9: Bar diagram comparing the number of total bolus doses
of fentanyl required between Group A and Group B
The total number of bolus doses of fentanyl required in Group A
was 16 and in Group B was 2.
Hence the total number of bolus doses of fentanyl required in
Group A was significantly higher when compared to Group B.
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Figure 10: Comparison of number of fentanyl bolus requirements
between  Group  A  and  Group  B  at  various  time
intervals using line diagram
The total number of bolus doses of fentanyl required in Group A
was 16 and in Group B was 2. Out of the 16 bolus doses of fentanyl
required in Group A, 12 bolus doses were administered within the first
30 minutes of peritoneal insufflation. In Group B both the bolus doses of
fentanyl were administered within the first 20 minutes of peritoneal
insufflation.
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Table 5: Comparison of mean of total number of bolus doses of
fentanyl required between Group A and Group B
Group A Group B P value
Bolus doses of
Fentanyl 0.55 0.07 0.001
The mean of total number of bolus doses of fentanyl required in
Group A was 0.55 while in Group B the mean was 0.07.
On analysing the data statistically, the p value was calculated as
p=0.001 for the mean of total number of bolus doses of fentanyl
required in Group A and Group B. All these values were <0.05, hence
the difference was statistically significant. Hence we concluded that the
mean of total number of bolus doses of fentanyl required in group A was
significantly higher when compared to group B.
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Figure 11: Bar diagram comparing the number of total bolus doses
of fentanyl required between Group A and Group B
The mean of total number of bolus doses of fentanyl required in
Group A was 0.55.
The mean of total number of bolus doses of fentanyl required in
Group B was 0.07.
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Table 6: Comparison of total number of episodes of hypotension
between Group A and Group B
Group A Group B P value
Number of Episodes of
Hypotension 1 23 0.000
The total number of episodes of hypotension encountered in
Group A was 1.
The total number of episodes of hypotension encountered in
Group B was 23.
On analysing the data statistically, the p value was calculated as
p=0.000 for the total number of episodes of hypotension between Group
A and Group B. All these values were <0.05, hence the difference was
statistically significant. Hence, the total number of hypotensive episodes
was significantly higher in group B when compared to group A.
The study protocol defined hypotension as MAP <25% of
baseline values on two consecutive readings within 2 – 3 minutes.
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Figure 12: Bar diagram comparing the total number of episodes of
hypotension between Group A and Group B
The total number of episodes of hypotension encountered in
Group A was 1 and in Group B was 23. Hence the number of episodes
of hypotension in Group B was significantly higher when compared to
Group A.
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Figure 13: Comparison of number of episodes of hypotension
between  Group  A  and  Group  B  at  various  time
intervals using line diagram
The total number of hypotensive episodes encountered in Group
B was 23. 16 of these 23 episodes were observed around 10 minutes
following intubation and before peritoneal insufflation. These
hypotensive episodes were transient and MAP returned to within 25% of
baseline values within 5 minutes of decrease in volatile concentration
and administration of a fluid bolus.
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Table 7: Comparison of heart rates between Group A and Group B
HEART RATE
TIME
INTERVAL
GROUP A GROUP B P VALUE
Baseline 85.72 92.83 .073
Preinduction 84.86 91.03 .076
Induction 85.41 92.90 .058
Intubation 101.38 98.77 .665
1 min 90.28 87.13 .351
5 min 84.31 83.23 .539
10 min 77.48 81.03 .534
15 min 78.14 79.20 .982
20 min 76.28 82.40 .100
25 min 76.24 80.07 .400
30 min 76.31 80.30 .421
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TIME
INTERVAL
GROUP A GROUP B P VALUE
40 min 74.24 79.50 .094
50 min 71.14 76.77 .093
60 min 73.66 77.27 .291
70 min 69.45 78.20 .008
80 min 72.56 77.24 .092
90 min 75.38 76.11 .762
100 min 74.71 76.72 .518
110 min 72.00 75.17 .605
120 min 70.00 78.50 .091
130 min 68.50 74.00 .519
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Figure 14: Comparison of heart rate variations between Group A
and Group B using line diagram
Maximal increase in heart rate in both the groups occurred
following laryngoscopy and endotracheal intubation. The increase in
mean heart rate in Group A was from 86 to 101 beats per minute while
in Group B mean heart rate increased from 93 to 99 beats per minute
during endotracheal intubation. But the increase was not statistically
significant and heart rates in both the groups remained within 25 % of
baseline values throughout the course of the study.
None of the patients in both the groups encountered bradycardia
(HR<50) both during intraoperative and postoperative periods.
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Table 8: Comparison of systolic blood pressure (mmHg) between
Group A and Group B
TIME
INTERVAL
GROUP A GROUP B P VALUE
Baseline 128.79 135.30 .135
Preinduction 128.76 134.60 .170
Induction 111.79 113.73 .500
Intubation 135.34 138.60 .439
1 min 116.10 122.53 .292
5 min 107.52 107.80 .773
10 min 113.38 101.77 .001
15 min 115.76 109.53 .262
20 min 117.14 124.37 .121
25 min 125.59 123.62 .624
30 min 128.52 125.23 .514
40 min 124.66 127.23 .727
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TIME
INTERVAL
GROUP A GROUP B P VALUE
50 min 123.24 124.30 .575
60 min 119.41 123.13 .379
70 min 119.41 118.40 .982
80 min 121.81 117.28 .358
90 min 121.05 115.46 .073
100 min 121.93 120.78 .901
110 min 127.17 118.08 .244
120 min 119.25 123.85 .648
130 min 114.50 121.33 1.000
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Figure 15: Comparison of systolic blood pressure between Group
A  and  Group  B  at  various  time  intervals  using  a  line
diagram
Maximal increase in SBP in both the groups occurred following
endotracheal intubation. But the values remained within 25 % of the
baseline values and the increase was found not to be statistically
significant. However, 19 patients in Group B encountered episodes of
fall in SBP to < 25% of baseline values (on two consecutive readings
within 2 – 3 minutes) around 10 minutes following tracheal intubation
prior to peritoneal insufflation. In Group A only one patient encountered
an episode of fall in SBP to < 25% of baseline values.
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Table 9: Comparison of diastolic blood pressure (mmHg)
between Group A and Group B
TIME
INTERVAL
GROUP A GROUP B P value
Baseline 84.28 85.47 .569
Preinduction 83.38 85.8 .194
Induction 73.1 75.03 .688
Intubation 88.66 92.1 .387
1 min 78.38 82 .061
5 min 71.14 72.3 .796
10 min 76.17 68.23 .021
15 min 80.24 77.93 .616
20 min 82.03 84.6 .216
25 min 88.83 86 .554
30 min 90.07 87.73 .688
40 min 90.03 86.47 .391
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TIME
INTERVAL
GROUP A GROUP B P value
50 min 86.83 85.67 .998
60 min 84.72 85.67 .761
70 min 82.83 80.93 .791
80 min 84.11 79.79 .651
90 min 83.14 78.04 .073
100 min 81.33 80.21 .758
110 min 81.8 76.85 .289
120 min 78.5 81.43 .527
130 min 75 78.75 1.000
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Figure 16: Comparison of diastolic blood pressure between Group
A and Group B at various time intervals using line
diagram
Maximal increase in DBP in both the groups occurred following
endotracheal intubation. But the values remained within 25 % of the
baseline values and the increase was found not to be statistically
significant. However, 19 patients in Group B encountered episodes of
fall in DBP to less 25% of baseline values (on two consecutive readings
within 2 – 3 minutes) around 10 minutes following tracheal intubation
prior to peritoneal insufflation. In Group A only one patient encountered
an episode of fall in DBP to less than 25% of baseline values. These
episodes of hypotension were transient and corrected by the
administration of a fluid bolus and a decrease in volatile concentration.
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Table 10: Comparison of mean arterial pressure (mmHg) between
Group A and Group B
TIME
INTERVAL
GROUP A GROUP B P VALUE
Baseline 97.45 101.5 .197
Preinduction 97.73 104.2 .085
Induction 85.17 89.97 .177
Intubation 106.83 107.23 .802
1 min 91.24 95.77 .049
5 min 82.72 82.87 .832
10 min 88.38 79.37 .007
15 min 90.59 90.1 .688
20 min 93.28 97.6 .118
25 min 101.28 99.43 .933
30 min 102.66 100.3 .791
40 min 101.52 99.17 .721
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TIME
INTERVAL
GROUP A GROUP B P VALUE
50 min 98.17 97.73 .676
60 min 95.86 96.87 .756
70 min 95.29 92.93 .640
80 min 96.63 91.86 .485
90 min 95.33 89.43 .023
100 min 92.33 93.61 .929
110 min 92.5 88 .467
120 min 91 98.33 .381
130 min 87 83 1.000
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Figure 17: Comparison of mean arterial pressure between Group
A and Group B at various time intervals using line
diagram
Maximal increase in MAP occurred following endotracheal
intubation. The mean rise in MAP was from 98 mmHg to 107 mmHg in
Group A while in Group B mean MAP values increased from 93mmHg
to 99mmHg. But the values remained within 25% of baseline values and
the increase found was not statistically significant. 16 patients in Group
A and 2 patients in Group B encountered episodes of hypertension
(MAP >25 % on two consecutive readings taken within 2 – 3min).
Majority of these episodes of hypertension in both the groups were
encountered within the first 30 minutes of peritoneal insufflation.
Maximal decrease in MAP was observed around 10 minutes
following tracheal intubation. Episodes of hypotension (MAP<25% of
baseline values for two consecutive readings within 2-3 minutes)
occurred in 19 patients in Group B while in Group A only one patient
encountered an episode of hypotension.
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Table 11: Comparison of the mean duration to recovery (eye
opening) and post operative sedation scores between
Group A and Group B
Group A Group B P value
Duration to eye
opening 14.41±3.11 16.87±1.17 0.000
Sedation score 2.00±0.00 2.17±0.38 0.023
The mean duration to eye opening in Group A and Group B was
14.41 and 16.87 minutes respectively.
The mean post-extubation sedation score in Group A was 2 and in
Group B was 2.17.
On analysing the data statistically, the p value is calculated was
p=0.000, and p=0.023 for duration to eye opening and post operative
sedation scores respectively. All these values were <0.05, hence the
difference was statistically significant between the two groups in terms
of duration to recovery and post operative sedation scores. Hence we
concluded that Dexmedetomidine at a dose of  0.6 µg/kg/hr results in an
increased post-extubation sedation score and prolongs the duration to
eye opening.
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CHAPTER 6
DISCUSSION
Laparoscopic surgeries under general anaesthesia are associated
with unique hemodynamic changes in the form of decreased venous
return and increased systemic vascular resistance leading to systemic
hypertension. This increases the need for deepening the plane of
anaesthesia and requires the use of vasodilators to counteract the rising
blood pressures .IAPs higher than 10 mm Hg due to peritoneal
insufflation with CO2 induces significant alterations in hemodynamics,
characterised by decrease in venous return ,increase in arterial pressures
,elevation of systemic and pulmonary vascular resistance .Heart rate
remains unchanged or increases only slightly .These hemodynamic
perturbations occur mainly at the beginning of peritoneal insufflation.
Various studies have been conducted with different
pharmacological interventions that result in reduced incidence of
tachycardia, hypertension during laparoscopic cholecystectomy and
provide a stable hemodynamic state with minimal undesirable effects.
Dexmedetomidine is a highly selective ?2 adrenoceptor agonist
which possesses analgesic , hypnotic, sedative, amnesic, anxiolytic and
sympatholytic properties without producing significant respiratory
depression. Its sympatholytic effect decreases mean arterial
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pressure(MAP) and heart rate by reducing norepinephrine release .In
addition Dexmedetomidine has the ability to reduce both the anaesthetic
and opioid analgesic requirements during the perioperative period .It
differs from clonidine in being 16 times more specific for ?2 receptors .
Dexmedetomidine due to such distinct properties can be used as an
anaesthetic adjuvant in the form of intravenous infusion for laparoscopic
surgeries.
This prospective randomized, double-blind study was conducted
in an attempt to compare and examine whether the administration of two
different doses of Dexmedetomidine to a commonly administered
balanced anaesthetic regimen reduces the perioperative analgesic and
volatile requirement. In this prospectively randomized, double-blind
study, we tested the hypothesis that Dexmedetomidine infusion would
produce dose related reductions in the anaesthetic and analgesic
requirements in patients undergoing laparoscopic cholecystectomy.
Previously various studies have evaluated different bolus doses of
Dexmedetomidine for premedication; however, dose-ranging studies are
essential when the drug is administered as a continuous infusion during
surgery. Dexmedetomidine has a high propensity to produce
hypotension  and / or bradycardia and hence it is important to determine
an infusion rate that would maximize the anaesthetic and analgesic-
sparing effect while minimizing the occurrence of adverse
cardiovascular side effects requiring therapeutic interventions. The
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addition of initial loading bolus dose of Dexmedetomidine resulted in a
high incidence of hypotension immediately following tracheal
intubation in a “pilot” experience before initiating the current protocol.
Hence we selected two doses of Dexmedetomidine at a constant
infusion rate of 0.2 µg/kg/hr and 0.6 µg/kg/hr and compared the
anaesthetic and analgesic sparing effects between the two groups. We
also compared the efficacy of two doses of Dexmedetomidine on the
maintenance of hemodynamic stability in patients undergoing
laparoscopic cholecystectomy.
Dexmedetomidine is a potent analgesic and reduces perioperative
fentanyl requirements in humans. The ?2 receptors located in the locus
ceruleus and the dorsal horn of spinal cord are implicated in the
analgesic action of Dexmedetomidine.?2 agonists and opioids act by
diverse mechanisms and their combination provides a synergistic
analgesic effect without increasing the incidence of respiratory
depression. The initial dose of fentanyl chosen in both groups was
1 µg/kg and bolus doses at 0.5 µg/kg up to a maximum dose of 2 µg/kg
in total were supplemented during the course of surgery when warranted
as per  the study protocol.  In our study the requirement of  fentanyl  was
reduced by 20% in the Dexmedetomidine 0.6 group compared to
Dexmedetomidine 0.2 group in our study. We also found that a
significantly higher number of fentanyl boluses were required in
Dexmedetomidine 0.2 group compared with Dexmedetomidine 0.6
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group. Therefore in our study we concluded that Dexmedetomidine at a
dose of 0.6 µg/kg/hr had better analgesic sparing properties when
compared to Dexmedetomidine at 0.2 µg/kg/hr. Ebert et al65 in 2000
studied the hemodynamic responses to increasing concentrations of
Dexmedetomidine and concluded that increasing concentrations of
Dexmedetomidine resulted in progressive increases in sedation and
analgesia . The results of this study are analogous to our study where
infusion rate of 0.6µg/kg/hr required significantly lesser amount of
fentanyl supplementation suggesting a greater analgesic effect of
Dexmedetomidine at a dose of 0.6 µg/kg/hr when compared to the
infusion at a rate of 0.2 µg/kg/hr. Our study could not comment on the
opioid sparing properties of Dexmedetomidine at dose of 0.2 µg/kg/hr
because it is a comparative study and not a controlled study.
It was postulated that a central alpha-2 adrenergic C4 isoreceptor
may be involved in the anaesthetic sparing effects of Dexmedetomidine.
We chose to compare the desflurane requirements between the two
groups and calculated the average inspiratory desflurane concentrations
of two groups .The average inspiratory concentrations were calculated
as the sum of products of the inspiratory concentrations and times
divided by the total anaesthesia time .We found a statistically significant
difference in the average inspiratory concentrations between the two
groups. The average inspiratory concentration required in group A
(Dexmedetomidine 0.2 µg/kg/hr) was 2.66 and the average inspiratory
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concentration required in group B (Dexmedetomidine  0.6 µg/kg/hr)
was 2.57. Hence it was concluded that Dexmedetomidine at a dose of
0.6 µg/kg/hr has statistically significant anaesthetic sparing effect when
compared to Dexmedetomidine at a dose of 0.2 µg/kg/hr. The
observations in our study were analogous to the findings of Feld et al62
who combined fentanyl or Dexmedetomidine with desflurane for
bariatric surgery and concluded that, desflurane concentrations
necessary to maintain bispectral index at 45 to 50 were decreased, and
blood pressure and heart rate were decreased with Dexmedetomidine
when compared with the fentanyl group. Anta et al64 in another study
showed that  the MAC of isoflurane was 47 % less with a high dose of
Dexmedetomidine than that without Dexmedetomidine. Again due to
the lack of a control group, our study could only conclude that
Dexmedetomidine decreases the requirements of volatile anaesthetics to
a greater degree at a dose of 0.6 µg/kg/hr when compared to a dose of
0.2 µg/kg/hr, but could not comment on the anaesthetic sparing effects
of Dexmedetomidine as a whole.
 Endotracheal intubation is associated with significant increase in
arterial pressure, heart rate, and plasma catecholamine concentrations.
Dexmedetomidine attenuated the sympathoadrenal response during
tracheal intubation effectively but did not completely abolish the
cardiovascular response. There was an increase in both MAP and heart
rate in both the groups after intubation .But the values remained within
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25 % of the baseline values and the increase found was not statistically
significant .The increase in mean heart rate in Dexmedetomidine
0.2 µg/kg/hr group was from 86 bpm to 101 bpm while that in
Dexmedetomidine 0.6 µg/kg/hr group was from 93 bpm to 99 bpm
during endotracheal intubation. The raise in MAP was from 98 mm Hg
to 107 mm Hg in Dexmedetomidine 0.2 µg/kg/hr group while that in
Dexmedetomidine 0.6 µg/kg/hr group was from 102 mmHg to 107
mmHg during intubation. Even though the increase in Heart rate and
MAP was observed in both the groups during endotracheal intubation,
the degree of increase was lesser in Dexmedetomidine 0.6 µg/kg/hr
group when compared to the Dexmedetomidine 0.2 µg/kg/hr group.
Dexmedetomidine in doses of 0.6 µg/kg/hr had greater sympathoadrenal
attenuation properties during endotracheal intubation when compared
with doses of 0.2 µg/kg/hr. Yildiz  et  al77 showed that a preinduction
intravenous dose of Dexmedetomidine 1 µg/kg, decreased the need for
thiopental and sevoflurane by 39% and 92% respectively, and
effectively blunted the hemodynamic responses to laryngoscopy.
However our study protocol does not include a preinduction bolus dose
of Dexmedetomidine and better attenuation of hemodynamic response
to laryngoscopy and intubation were observed in Dexmedetomidine at
an infusion rate of 0.6 µg/kg/hr, but none of the groups completely
abolished the intubation stress response.
94
The use of intraoperative Dexmedetomidine may increase the
hemodynamic stability due to the attenuation of stress-induced
hemodynamic response to intubation, peritoneal insufflation and
emergence from anaesthesia. The MAPs were compared at various time
intervals between the two groups. Intubation stress response evoked a
10% increase in MAP in Dexmedetomidine 0.2 µg/kg/hr group from the
baseline values while Dexmedetomidine 0.6 µg/kg/hr group showed
only a 5 % increase in MAP from the baseline values. Mean heart rates
between the two groups were compared and Dexmedetomidine
0.2 µg/kg/hr group recorded a mean increase in heart of 20% above
baseline value on endotracheal intubation, while the mean increase in
Dexmedetomidine 0.6 µg/kg/hr group was 5% above the baseline values
. None of the groups encountered a significant increase in heart rate on
peritoneal insufflations. None of the patients in both the groups
encountered a significant bradycardia with a heart rate of less than
50bpm. Dexmedetomidine at a dose of 0.6µg/kg/hr had better
attenuation of sympathoadrenal response to endotracheal intubation
when compared to Dexmedetomidine at doses of 0.2 µg/kg/hr, but did
not completely obtund the response to endotracheal intubation.
The maximum decrease in MAP in both the groups was observed
around 10 minutes following intubation and before peritoneal
insufflations . 50 % of patients in Dexmedetomidine 0.6 µg/kg/hr group
showed a decrease in MAP greater than 25 % from the baseline values
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before peritoneal insufflations , requiring administration of a fluid bolus
and a decrease in volatile concentration .However this decrease was
transient and MAP values returned to within 25% of baseline values,
within 5 minutes of reducing the volatile concentrations and
administration of a fluid bolus. None of the patients in
Dexmedetomidine 0.2 µg/kg/hr group showed a decrease in MAP
greater than 25% from the baseline values before peritoneal
insufflations. hroughout the course of the surgery 19 patients in
Dexmedetomidine 0.6 µg/kg/hr group required a decrease in volatile and
administration of a fluid bolus for correction of hypotension. These
hypotensive episodes were transient and MAP returned to within 25% of
the baseline values within 5 minutes of decrease in volatile
concentration and administration of a fluid bolus. While in
Dexmedetomidine 0.2 µg/kg/hr group only 1 patient had a hypotensive
episode requiring a fluid bolus and a decrease in volatile concentration.
The number of hypotensive episodes encountered in Dexmedetomidine
0.6 µg/kg/hr group were found to be significantly higher when
compared to the Dexmedetomidine 0.2 µg/kg/hr group. This could be
attributed to the greater sympatholytic effect of Dexmedetomidine at
0.6 µg/kg/hr compared to 0.2 µg/kg/hr. Ebert et al65 in 2000 studied the
hemodynamic responses to increasing concentrations of
Dexmedetomidine and concluded that increasing concentrations of
Dexmedetomidine in humans resulted in progressive increases in
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sedation and analgesia and progressive decreases in heart rate, cardiac
output and memory. The results of this study are analogous to our study
where infusion doses of 0.6 µg/kg/hr produced greater episodes of
decrease in MAP when compared to an infusion rate of 0.2 µg/kg/hr.
Hypertensive  episodes  with  MAP  values  rising  to  over  25%  of
baseline values were observed in 15 patients in our study with 13
patients in Dexmedetomidine 0.2 µg/kg/hr group and 2 patients in
Dexmedetomidine 0.6 µg/kg/hr group .These hypertensive episodes
were treated by supplementing fentanyl boluses in doses of 0.5 µg/kg up
to a maximum of 2 µg/kg. All the hypertensive episodes resolved with
fentanyl supplementation and none of the cases required an increase in
volatile concentration or propofol supplementation in our study
.Hypertensive episodes occurred within 30 min of peritoneal
insufflations in 8 of the 13 patients in Dexmedetomidine 0.2 µg/kg/hr
group .In Dexmedetomidine 0.6 µg/kg/hr group 2 patients who
encountered hypertension had these episodes within 20 min of
peritoneal insufflations. The number of hypertensive episodes in
Dexmedetomidine 0.2 µg/kg/hr group was significantly higher when
compared to Dexmedetomidine 0.6 µg/kg/hr group. Out of the 13
patients in Dexmedetomidine 0.2 µg/kg/hr group who encountered
intraoperative hypertension, 3 patients required administration of two
bolus doses of fentanyl at 0.5 µg/kg to correct hypertension, while in the
remaining 10 patients administration of a single bolus dose of fentanyl
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at 0.5 µg/kg was sufficient to correct the hypertensive episode.
Hypertensive episode that occurred in 2 patients in Dexmedetomidine
0.6 µg/kg/hr group were treated by the administration of a single bolus
dose of fentanyl at 0.5 µg/kg. Thus concluding that Dexmedetomidine in
doses of 0.6 µg/kg/hr has better sympathoadrenal stress response
attenuating properties when compared to Dexmedetomidine at a dose of
0.2 µg/kg/hr. Again the observations in our study are analogous to the
study done by Ebert et al65 in 2000 where he showed that progressively
increasing concentrations of Dexmedetomidine resulted in progressive
increase in sedation and analgesia and progressive decreases in heart
rate, cardiac output and memory. Thus Dexmedetomidine at 0.6
µg/kg/hr has better analgesic and sympatholytic properties when
compared to Dexmedetomidine at doses of 0.2 µg/kg/hr.
Post extubation sedation scores were studied in the two groups.
All patients in Dexmedetomidine 0.2 µg/kg/hr had Ramsay sedation
score of 2; whereas 5 patients among the 29 patients in
Dexmedetomidine 0.6 µg/kg/hr group had a sedation score of 3. This
difference in the post extubation sedation score between the two groups
was statistically significant. All patients in both the groups at the end of
the second hour following extubation had a sedation score of 2. This
was in accordance to the study done by Ebert et al65 who showed that
progressively increasing concentrations of Dexmedetomidine result in
progressive increase in sedation and analgesia. The mean duration for
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eye opening after the cessation of Dexmedetomidine infusion showed a
significant increase in Dexmedetomidine 0.6 µg/kg/hr at 16.87min in
our study compared to the Dexmedetomidine 0.2 µg/kg/hr group where
the mean duration was 14.41 min. Thus Dexmedetomidine at 0.6
µg/kg/hr resulted in a progressive increase in sedation scores and the
time for eye opening when compared to Dexmedetomidine at 0.2
µg/kg/hr.
Dexmedetomidine was well tolerated and no serious side effects
or adverse reactions occurred both during the intraoperative and post-
operative periods in the present study.
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CONCLUSION
Dexmedetomidine at an infusion rate of  0.6 µg/kg/hr has a better
analgesic and anaesthetic sparing property and a better hemodynamic
stabilization property when compared to an infusion rate of
0.2 µg/kg/hr, with episodes of transient hypotension, increased
postoperative sedation scores, with no serious side effects or adverse
reactions.
Hence I conclude that Dexmedetomidine administered at an
infusion rate of 0.6 µg/kg/hr may serve as an ideal anaesthetic adjuvant
in patients undergoing laparoscopic cholecystectomy.
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PROFORMA
NAME: AGE/SEX: IP NO.:
DATE: Wt.: GROUP:
DIAGNOSIS: SURGERY:
BRIEF HISTORY: COEXISTING ILLNESS:
EXAMINATION
PR: CVS:
BP: RS:
RR: AIRWAY:
INVESTIGATIONS
Hb: Blood urea:
Urine alb: Sugar :
Sr. Creatinine: Electrolytes:
X-ray chest: ECG:
ANAESTHESIA DETAILS
Premedication : Group :
Induction : Intubation :
Maintenance : Duration of surgery:
PROFORMA
Parameters Baseline Preinduction Induction Intubation 1
min
5
min
10
min
15
min
20
min
25
min
30
min
40
min
50
min
60
min
70
min
80
min
90
min
100
min
110
min
120
min
130
min
140
min
HR
SBP
DBP
MAP
SPO2
ETCO2
DESFLUR
FENTANYL
DEXMED
TOTAL FENTANYL : INTRA-ABDOMINAL PRESSURE:
AVERAGE INSPIRATORY DESFLURANE CONC: TOTAL IV FLUIDS:
TIME TO EYE OPENING / TRACHEAL EXTUBATION:
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INFORMATION SHEET
1. You have been accepted.
2. We are conducting a study on “Dexmedetomidine for
Laparoscopic Cholecystectomy – Comparison between two doses
on the effects on sympathoadrenal response and anaesthetic
sparing properties”, Stanley Medical College, Chennai and for
that you may be valuable to us.
3. We are selecting certain patients and if you are found eligible, we
may be using you to perform procedures which will not harm you.
4. The privacy of the patients in the research will be maintained
throughout the study. In the event of any publication or
presentation resulting from the research, no personally
identifiable information will be shared.
5. Taking part in this study is voluntary. You are free to decide
whether  to  participate  in  this  study  or  to  withdraw  at  any  time;
your decision will not result in any loss of benefits to which you
are otherwise entitled.
Date:
Signature of Investigator Signature of Participant
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MASTER CHART
SL No. Group Date Name IP No. Age Sex Weight(kg) Surgery ASA
Duration of
Surgery
(mins)
Dexmedetomidin
e infusion
(ug/kg/hr)
Induction
1 B 11/18/2013 Lalitha 38938 28 F 63 Lap . Cholecystectomy I 90 0.6
Propofol 100 mg/Fentanyl 60
ug/Atracurium 25 mg
2 A 11/21/2013 Nazina Begum 37986 27 F 62 Lap . Cholecystectomy I 80 0.2
Propofol 100 mg/Fentanyl 60
ug/Atracurium 25 mg
3 A 11/21/2013 Anbarasan 39731 23 M 71 Lap . Cholecystectomy I 80 0.2
Propofol 100 mg/Fentanyl 70
ug/Atracurium 25 mg
4 A 11/22/2013 Ilakkiya 37021 22 F 59 Lap . Cholecystectomy I 100 0.2
Propofol 100 mg/Fentanyl 60
ug/Atracurium 25 mg
5 B 11/29/2013 Maheswari
P a g e  |
140784 42 F 61 Lap . Cholecystectomy I 70 0.6
Propofol 100 mg/Fentanyl 60
ug/Atracurium 25 mg
6 B 1/7/2014 Saravana kumar 1400619 17 M 46 Lap . Cholecystectomy I 120 0.6
Propofol 100 mg/Fentanyl 50
ug/Atracurium 25 mg
7 A 1/9/2013 Lingaraj 1401028 20 M 51 Lap . Cholecystectomy I 110 0.2
Propofol 100 mg /Fentanyl 50
ug/Atracurium 25 mg
8 B 1/10/2014 Radha 1400803 42 F 61 Lap . Cholecystectomy I 110 0.6
Propofol 120 mg/Fentanyl 60
ug/Atracurium 30mg
9 A 1/10/2014 Roja 1401803 25 F 52 Lap . Cholecystectomy I 70 0.2
Propofol 100 mg/ Fentanyl 50
ug/Atracurium 25 mg
10 A 1/11/2014 Nazima 1400863 32 F 61 Lap . Cholecystectomy I 80 0.2
Propofol 100 mg/Fentanyl 60
ug/Atracurium 25 mg
11 A 1/21/2014 Mukesh 1402523 20 M 62 Lap . Cholecystectomy I 90 0.2
Propofol 120 mg/Fentanyl 60
ug/Atracurium 30mg
12 A 1/21/2014 Hemalatha 1402186 19 F 59 Lap . Cholecystectomy I 70 0.2
Propofol 120 mg/Fentanyl 60
ug/Atracurium 30mg
13 B 1/24/2014 Regina 132412 32 F 52 Lap . Cholecystectomy I 120 0.6
Propofol 100 mg/Fentanyl 50
ug/Atracurium 25 mg
14 A 1/29/2014 Elumalai 1403497 47 M 61 Lap . Cholecystectomy I 110 0.2
Propofol 120 mg/Fentanyl 60
ug/Atracurium 30mg
15 A 2/3/2014 Mariraj 1404479 47 M 75 Lap . Cholecystectomy I 190 0.2
Propofol 150 mg/Fentanyl
75ug/Atracurium 40 mg
16 B 2/6/2014 Revathy 140556 18 F 48 Lap . Cholecystectomy I 90 0.6
Propofol 100 mg/ Fentanyl 50
ug/Atracurium 25 mg
17 A 2/12/2014 Selvi 1402843 50 F 51 Lap . Cholecystectomy I 80 0.2
Propofol 100 mg/Fentanyl 60
ug/Atracurium 25 mg
18 A 2/19/2014 Tamaraiselvi 1405205 42 F 59 Lap . Cholecystectomy I 110 0.2
Propofol 120 mg/Fentanyl 60
ug/Atracurium 30mg
19 A 2/20/2014 Devika 1407001 36 F 61 Lap . Cholecystectomy I 120 0.2
Propofol 120 mg/Fentanyl
60ug/Atracurium 30mg
20 B 2/22/2014 Vignesh 8496 23 M 62 Lap . Cholecystectomy I 80 0.6
Propofol 120mg/Fentanyl
60ug/Atracurium 30 mg
21 B 2/27/2014 Annapoorani 8393 50 F 61 Lap . Cholecystectomy I 90 0.6
Propofol 120mg/Fentanyl
60ug/Atracurium 30 mg
114
SL No. Group Date Name IP No. Age Sex Weight(kg) Surgery ASA
Duration of
Surgery
(mins)
Dexmedetomidin
e infusion
(ug/kg/hr)
Induction
22 B 2/28/2014 Jainu 7917 23 F 52 Lap . Cholecystectomy I 90 0.6
Propofol 100mg/Fentantyl
50ug/Atracurium 25mg
23 A 3/4/2014 Yamuna 10100 20 F 49 Lap . Cholecystectomy I 80 0.2
Propofol 100mg/Fentantyl
50ug/Atracurium 25mg
24 A 3/9/2014 Jagadha 10894 50 F 51 Lap . Cholecystectomy I 100 0.2
Propofol 100mg/Fentantyl
50ug/Atracurium 25mg
25 A 3/10/2014 Dharani 21192 30 F 59 Lap . Cholecystectomy I 80 0.2
Propofol 120mg/Fentanyl
60ug/Atracurium 30 mg
26 A 5/7/2014 Anusha 21347 19 F 52 Lap . Cholecystectomy I 90 0.2
Propofol 100mg/Fentantyl
50ug/Atracurium 25mg
27 B 5/9/2014 Selvi 21388 50 F 61 Lap . Cholecystectomy I 130 0.6
Propofol 120mg/Fentanyl
60ug/Atracurium 30 mg
28 B 5/10/2014 Sindhu 23674 15 F 51 Lap . Cholecystectomy I 90 0.6
Propofol 100mg/Fentantyl
50ug/Atracurium 25mg
29 B 3/11/2014 Balakrishnan 8925 50 M 73 Lap . Cholecystectomy I 90 0.6
Propofol 150 mg/Fentanyl
75ug/Atracurium 40 mg
30
A 5/13/2014 Thasriya nasllen 21456 45 F 59 Lap . Cholecystectomy I 100 0.2
Propofol 120mg/Fentanyl
60ug/Atracurium 30 mg
31 B 5/17/2014 Sathya 21763 30 F 62 Lap . Cholecystectomy I 110 0.6
Propofol 120mg/Fentanyl
60ug/Atracurium 30 mg
32 B 5/20/2014 Uma 2447 45 F 58 Lap . Cholecystectomy I 100 0.6
Propofol 120mg/Fentanyl
60ug/Atracurium 30 mg
33 A 5/19/2014 Deepa 23498 30 F 63 Lap . Cholecystectomy I 90 0.2
Propofol 120mg/Fentanyl
60ug/Atracurium 30 mg
34 A 5/21/2014 Selvi 19859 30 F 60 Lap . Cholecystectomy I 90 0.2
Propofol 120mg/Fentanyl
60ug/Atracurium 30 mg
35 B 2/25/2014 Sampoorna 23604 36 F 62 Lap . Cholecystectomy I 90 0.6
Propofol 120mg/Fentanyl
60ug/Atracurium 30 mg
36 B 2/23/2014 Geetha 20849 24 F 58 Lap . Cholecystectomy I 90 0.6
Propofol 120mg/Fentanyl
60ug/Atracurium 30 mg
37 A 2/11/2014 Pankajam 19201 36 F 64 Lap . Cholecystectomy I 100 0.2
Propofol 130mg/Fentanyl
65ug/Atracurium 35 mg
38 A 2/6/2014 Rathinam 25192 42 F 59 Lap . Cholecystectomy I 100 0.2
Propofol 120mg/Fentanyl
60ug/Atracurium 30 mg
39 B 1/22/2014 Rajni 27243 29 F 62 Lap . Cholecystectomy I 110 0.6
Propofol 120mg/Fentanyl
60ug/Atracurium 30 mg
40 A 1/28/2014 Seetha 23491 34 F 57 Lap . Cholecystectomy I 100 0.2
Propofol 120mg/Fentanyl
60ug/Atracurium 30 mg
41 B 5/22/2014 Govindammal 25314 45 F 61 Lap . Cholecystectomy I 110 0.6
Propofol 120mg/Fentanyl
60ug/Atracurium 30 mg
42 A 3/5/2014 Ponmudi 4223 39 F 52 Lap . Cholecystectomy I 80 0.2
Propofol 100mg/Fentantyl
50ug/Atracurium 25mg
43 B 5/15/2014 Kuppam 8501 45 M 69 Lap . Cholecystectomy I 110 0.6
Propofol 140mg/Fentanyl
70ug/Atracurium 40mg
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SL No. Group Date Name IP No. Age Sex Weight(kg) Surgery ASA
Duration of
Surgery
(mins)
Dexmedetomidin
e infusion
(ug/kg/hr)
Induction
44 A 3/11/2014 Kavitha 10815 44 F 52 Lap . Cholecystectomy I 100 0.2
Propofol 100mg/Fentantyl
50ug/Atracurium 25mg
45 A 2/14/2014 Rani 23356 49 F 59
Lap . Cholecystectomy
I 100 0.2
Propofol 120mg/Fentanyl
60ug/Atracurium 30 mg
46 B 5/23/2014 Vinothavalli 25714 45 F 62 Lap . Cholecystectomy I 100 0.6
Propofol 120mg/Fentanyl
60ug/Atracurium 30 mg
47 B 5/23/2014 Rekha 25434 33 F 58 Lap . Cholecystectomy I 100 0.6
Propofol 120mg/Fentanyl
60ug/Atracurium 30 mg
48 B 1/10/201774 Sundaram 22769 21 M 62 Lap . Cholecystectomy I 100 0.6
Propofol 120mg/Fentanyl
60ug/Atracurium 30 mg
49 B 1/22/2014 Hemalatha 21387 28 F 57 Lap . Cholecystectomy I 80 0.6
Propofol 120mg/Fentanyl
60ug/Atracurium 30 mg
50 A 1/24/2014 Suresh 26759 30 M 65 Lap . Cholecystectomy I 100 0.2
Propofol 130mg/Fentanyl
65ug/Atracurium 35 mg
51 A 2/2/2014 Sarathy 24959 36 M 62 Lap . Cholecystectomy I 110 0.2
Propofol 120mg/Fentanyl
60ug/Atracurium 30 mg
52 A 2/21/2012 Govindammal 23408 40 F 57 Lap . Cholecystectomy I 90 0.2
Propofol 120mg/Fentanyl
60ug/Atracurium 30 mg
53
B 1/29/2014 Ramya 24351 42 F 52 Lap . Cholecystectomy I 110 0.6
Propofol 100mg/Fentantyl
50ug/Atracurium 25mg
54 B 1/6/2014 Deepa 28421 32 F 61 Lap . Cholecystectomy I 120 0.6
Propofol 120mg/Fentanyl
60ug/Atracurium 30 mg
55 B 5/15/2014 Padma 21321 39 F 59 Lap . Cholecystectomy I 100 0.6
Propofol 120mg/Fentanyl
60ug/Atracurium 30 mg
56 B 5/11/2014 Charumathi 26543 43 F 63 Lap . Cholecystectomy I 100 0.6
Propofol 120mg/Fentanyl
60ug/Atracurium 30 mg
57 B 2/23/2014 Ganesh 28501 28 M 68 Lap . Cholecystectomy I 80 0.6
Propofol 140mg/Fentanyl
70ug/Atracurium 40mg
58 B 5/29/2014 Sasikala 27835 23 F 52 Lap . Cholecystectomy I 110 0.6
Propofol 100mg/Fentantyl
50ug/Atracurium 25mg
59 B 5/31/2014 Selvi 28123 27 F 59 Lap . Cholecystectomy I 110 0.6
Propofol 120mg/Fentanyl
60ug/Atracurium 30 mg
60 A 6/1/2014 Menaka 26444 50 F 51 Lap . Cholecystectomy I 80 0.2
Propofol 100 mg/Fentanyl 60
ug/Atracurium 25 mg
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1 B 11/18/2013 Lalitha 101 95 77 93 81 76 66 63 61 61 60 64 69 75 74 81 82
2 A 11/21/2013 Nazina Begum 84 80 78 110 91 83 85 80 83 84 86 80 70 83 72 75
3 A 11/21/2013 Anbarasan 84 80 78 110 91 83 80 81 85 82 86 80 70 83 72 80
4 A 11/22/2013 Ilakkiya 95 90 84 113 94 91 81 81 82 80 80 79 81 76 71 70 82 84
5 B 11/29/2013 Maheswari 97 99 106 96 95 90 72 65 65 64 62 63 63 62 68
6 B 1/7/2014 Saravana kumar 69 78 74 88 76 69 59 64 65 64 62 60 58 58 56 56 59 52 50 73
7 A 1/9/2013 Lingaraj 68 76 78 81 83 85 74 75 81 71 75 75 79 84 69 72 74 69 77
8 B 1/10/2014 Radha 74 81 106 96 69 63 59 73 73 81 81 79 83 81 83 76 72 71 74 75 76
9 A 1/10/2014 Roja 84 84 94 99 97 83 90 98 78 79 83 75 68 76 74
10 A 1/11/2014 Nazima 94 87 82 94 96 97 82 85 86 84 82 79 75 72 77 88 102
11 A 1/21/2014 Mukesh 68 68 77 111 92 62 77 77 55 54 51 56 56 56 56 75 76
12 A 1/21/2014 Hemalatha 80 72 66 97 80 82 75 72 72 76 74 70 69 68 71
13 B 1/24/2014 Regina 92 93 105 111 102 107 106 107 107 102 101 102 99 96 101 95 92 98 88 91
14 A 1/29/2014 Elumalai 77 79 81 115 93 91 87 87 72 65 68 67 65 72 68 70 66 77 72
15 A 2/3/2014 Mariraj 71 75 71 87 74 65 61 61 56 52 53 61 52 58 55 56 56 60 64 66 61 60 62 59 59 60 56
16 B 2/6/2014 Revathy 77 88 101 106 113 92 96 99 92 95 92 85 84 81 82 78 71
17 A 2/12/2014 Selvi 69 66 70 93 75 54 50 58 62 64 63 63 63 61 64 64
18 A 2/19/2014 Tamaraiselvi 86 80 70 96 75 75 71 65 64 71 75 64 69 72 71 79 72 70
19 A 2/20/2014 Devika 74 78 89 84 71 65 63 59 66 60 62 58 74 98 66 62 63 57 63 74 76
20 B 2/22/2014 Vignesh 72 71 70 74 73 70 68 64 71 61 64 68 63 62 64 68 64
21 B 2/27/2014 Annapoorani 108 92 95 96 80 89 82 80 88 80 82 83 79 80 83 85 78
22 B 2/28/2014 Jainu 86 84 99 99 106 95 96 85 87 84 94 87 97 90 87 78 81
23 A 3/4/2014 Yamuna 99 104 98 104 101 95 91 102 100 99 91 95 86 84 72 78
24 A 3/9/2014 Jagadha 94 106 101 104 98 92 80 76 71 68 69 71 62 63 60 68
25 A 3/10/2014 Dharani 88 90 90 82 83 74 74 72 75 79 92 98 67 65 66 69 65
26 A 5/7/2014 Anusha 109 103 110 126 106 106 88 84 86 110 106 92 89 92 90 86 84
27 B 5/9/2014 Selvi 98 96 86 92 83 81 78 75 88 85 83 82 78 76 93 72 73 70 70 70 70
28 B 5/10/2014 Sindhu 79 84 72 110 96 88 77 66 72 74 72 72 73 72 75 84 86
29 B 3/11/2014 Balakrishnan 65 64 68 74 73 63 67 71 67 65 69 68 63 65 61 65 69
30 A 5/13/2014 Thasriya nasllen 100 90 92 89 76 74 68 58 58 56 60 59 65 60 65 70 86 85
31 B 5/17/2014 Sathya 110 98 92 112 102 79 70 68 76 70 71 85 80 74 77 80 90 81 81
32 B 5/20/2014 Uma 110 118 112 116 89 81 89 95 96 89 80 80 78 91 90 84 80 86
33 A 5/19/2014 Deepa 108 102 110 125 106 105 88 83 86 110 106 92 87 92 90 86 84
34 A 5/21/2014 Selvi 94 87 86 95 96 97 75 82 85 86 84 82 78 76 73 78 89
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35 B 2/25/2014 Sampoorna 110 98 97 98 82 91 84 82 90 82 84 85 81 82 85 87 80
36 B 2/23/2014 Geetha 112 100 99 100 84 93 86 84 92 84 86 87 83 84 89 82 84
37 A 2/11/2014 Pankajam 95 88 85 95 97 98 76 83 86 87 85 83 80 76 73 78 89 101
38 A 2/6/2014 Rathinam 94 87 84 94 96 97 75 82 85 86 84 82 79 75 72 77 88 100
39 B 1/22/2014 Rajni 92 90 105 110 101 106 113 105 106 106 101 110 98 95 100 94 91 99 87
40 A 1/28/2014 Seetha 74 79 81 115 93 91 87 87 72 65 68 67 65 72 68 70 71 66 77 70
41 B 5/22/2014 Govindammal 104 95 98 95 85 84 85 80 80 80 84 85 74 70 70 70 70 71 75
42 A 3/5/2014 Ponmudi 98 103 107 103 100 94 90 101 99 98 90 94 85 83 76 77
43 B 5/15/2014 Kuppam 103 94 97 94 84 83 84 79 79 79 83 84 73 69 69 69 69 70 74
44 A 3/11/2014 Kavitha 95 107 102 105 99 93 81 77 72 71 72 69 70 72 63 64 61 59
45 A 2/14/2014 Rani 69 67 70 93 75 64 60 68 62 69 63 63 61 64 64 64 63 65
46 B 5/23/2014 Vinothavalli 120 105 108 110 100 98 95 92 98 101 104 89 79 84 82 85 80 85
47 B 5/23/2014 Rekha 118 103 106 108 98 96 93 90 96 99 102 87 77 82 80 83 78 83
48 B 1/10/2014 Sundaram 69 78 74 87 75 68 72 60 62 64 63 59 57 57 55 55 58 57
49 B 1/22/2014 Hemalatha 81 73 67 98 81 83 76 73 73 77 75 71 70 69 72 72
50 A 1/24/2014 Suresh 68 68 77 111 92 62 77 64 77 55 54 51 56 56 56 56 58 76
51 A 2/2/2014 Sarathy 74 79 81 115 93 91 87 87 72 65 68 67 65 72 68 70 66 77 79
52 A 2/21/2012 Govindammal 93 86 85 94 95 96 74 81 84 85 83 81 77 75 72 77 88
53 B 1/29/2014 Ramya 92 90 104 110 101 106 113 105 106 106 101 100 101 98 95 100 94 91 97 87
54 B 1/6/2014 Deepa 74 81 106 96 69 63 62 59 73 81 81 79 83 81 83 76 72 71 74 75 76
55 B 5/15/2014 Padma 110 118 112 116 89 81 89 95 96 81 80 80 78 91 90 84 80 86
56 B 5/11/2014 Charumathi 108 116 110 114 87 79 87 93 94 79 78 78 76 89 88 82 78 84
57 B 2/23/2014 Ganesh 72 71 70 74 73 70 68 64 71 61 64 68 63 62 64 68 64
58 B 5/29/2014 Sasikala 82 80 81 110 97 88 77 73 80 82 78 76 77 67 65 68 67 61 68
59 B 5/31/2014 Selvi 100 98 90 80 70 65 62 67 68 65 72 69 66 75 65 63 69 65 64
60 A 6/1/2014 Menaka 69 66 70 93 75 54 50 58 62 64 63 63 63 61 64 64
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1 B 11/18/2013 Lalitha 126 121 114 124 114 97 92 90 91 88 90 84 93 94 96 106 108
2 A 11/21/2013 Nazina Begum 134 130 126 138 126 117 125 126 129 129 128 125 127 128 124 124
3 A 11/21/2013 Anbarasan 134 129 126 136 126 117 125 126 129 129 128 125 127 128 114 125
4 A 11/22/2013 Ilakkiya 110 108 100 110 100 91 122 118 112 91 82 108 112 110 112 106 114 122
5 B 11/29/2013 Maheswari 161 150 146 151 140 136 123 120 114 114 117 153 141 142 138
6 B 1/7/2014 Saravana kumar 122 122 112 126 119 100 94 81 94 94 99 105 104 100 102 101 103 102 99 122
7 A 1/9/2013 Lingaraj 121 122 108 130 121 110 118 123 124 123 126 128 119 119 119 121 115 117 118 114
8 B 1/10/2014 Radha 134 134 114 148 120 108 102 154 161 153 151 154 146 152 141 134 139 142 132 110 122
9 A 1/10/2014 Roja 112 117 113 134 117 101 100 119 136 137 135 125 116 119 114
10 A 1/11/2014 Nazima 127 119 119 134 114 113 134 125 126 119 123 123 115 115 112 119 106
11 A 1/21/2014 Mukesh 133 144 122 118 151 122 114 131 117 130 142 140 142 116 122 136 134 126
12 A 1/21/2014 Hemalatha 123 124 114 134 121 114 95 95 115 124 126 125 118 117 128
13 B 1/24/2014 Regina 134 134 117 143 132 111 127 130 138 145 136 132 130 131 127 130 102 121 124 124
14 A 1/29/2014 Elumalai 144 146 123 165 142 117 106 108 100 131 120 153 135 139 135 150 147 142 140
15 A 2/3/2014 Mariraj 122 117 97 109 100 107 104 104 112 104 94 89 93 95 95 97 100 101 103 110 101 103 99 102 98 95 104
16 B 2/6/2014 Revathy 113 123 107 131 120 115 123 149 126 119 112 104 130 100 99 107 114
17 A 2/12/2014 Selvi 124 123 105 140 105 88 97 103 126 127 112 11 114 101 107 119
18 A 2/19/2014 Tamaraiselvi 126 122 89 140 98 85 96 87 93 107 161 146 151 121 142 113 133 116
19 A 2/20/2014 Devika 121 126 112 124 112 100 99 96 100 141 130 123 132 148 135 122 118 108 121 113 128
20 B 2/22/2014 Vignesh 123 113 84 104 95 89 99 96 107 112 117 118 115 111 105 108 114
21 B 2/27/2014 Annapoorani 161 171 150 165 132 119 93 118 147 128 126 136 126 121 131 129 121
22 B 2/28/2014 Jainu 126 123 104 127 129 105 103 105 94 93 111 118 117 106 111 101 119
23 A 3/4/2014 Yamuna 134 135 105 134 113 106 105 125 128 127 121 120 108 109 107 118
24 A 3/9/2014 Jagadha 140 144 124 151 136 99 119 114 115 113 154 123 121 127 118 117 115 121
25 A 3/10/2014 Dharani 132 126 124 164 148 117 117 114 113 131 139 124 117 119 125 126 117
26 A 5/7/2014 Anusha 119 119 94 125 106 99 122 108 112 153 151 138 118 117 119 118 117
27 B 5/9/2014 Selvi 154 158 116 149 115 107 81 139 155 147 145 149 124 126 125 109 107 128 106 110 110
28 B 5/10/2014 Sindhu 100 95 98 109 102 97 90 84 115 113 123 119 128 119 125 103 105
29 B 3/11/2014 Balakrishnan 139 136 114 174 125 102 81 113 155 154 155 148 129 130 103 108 108
30 A 5/13/2014 Thasriya nasllen 141 149 129 109 117 119 115 109 119 126 153 156 150 125 132 113 109 113
31 B 5/17/2014 Sathya 140 144 124 144 145 124 99 117 123 133 133 132 130 129 123 124 124 125 124
32 B 5/20/2014 Uma 150 160 140 160 151 109 100 124 140 151 152 156 156 145 139 135 134 136
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33 A 5/19/2014 Deepa 118 117 93 124 105 98 121 107 111 152 151 138 117 116 119 117 118
34 A 5/21/2014 Selvi 128 120 102 135 115 114 110 135 126 127 120 124 124 116 116 113 120
35 B 2/25/2014 Sampoorna 159 169 148 165 130 117 91 116 145 126 124 134 124 119 129 127 119
36 B 2/23/2014 Geetha 154 164 143 160 125 112 86 11 140 121 119 129 119 114 124 122 114
37 A 2/11/2014 Pankajam 128 120 109 135 4 110 135 126 117 120 124 124 116 116 113 120 107
38 A 2/6/2014 Rathinam 127 119 108 134 114 113 104 134 125 116 119 123 123 115 115 112 119 106
39 B 1/22/2014 Rajni 134 134 117 143 132 111 127 130 138 145 136 132 130 131 127 130 112 121 124 129
40 A 1/28/2014 Seetha 144 146 123 145 142 117 106 108 100 131 120 153 135 139 135 150 145 147 142 140
41 B 5/22/2014 Govindammal 123 122 121 121 108 121 109 96 95 90 94 94 94 115 96 96 109 108 112
42 A 3/5/2014 Ponmudi 133 134 104 133 112 105 104 124 127 126 120 119 107 108 106 117
43 B 5/15/2014 Kuppam 122 121 120 120 107 120 108 95 94 89 93 93 93 114 95 95 108 107 111
44 A 3/11/2014 Kavitha 141 145 125 150 137 100 120 115 116 114 154 124 122 128 119 118 116 122
45 A 2/14/2014 Rani 124 123 105 143 105 105 145 103 126 127 112 111 114 101 107 119 111 120
46 B 5/23/2014 Vinothavalli 155 152 107 150 119 98 98 122 128 129 132 127 125 125 119 117 115 117
47 B 5/23/2014 Rekha 153 150 105 148 117 96 96 120 126 127 130 125 123 123 117 115 113 115
48 B 1/10/2014 Sundaram 121 121 111 125 118 99 97 93 93 93 93 98 104 103 99 101 100 102 101
49 B 1/22/2014 Hemalatha 123 124 11 134 121 114 95 95 115 124 126 125 118 117 128 127
50 A 1/24/2014 Suresh 124 145 119 152 123 104 115 132 118 131 143 141 143 117 123 137 135 127
51 A 2/2/2014 Sarathy 143 145 122 144 142 116 105 107 99 129 119 152 134 138 134 149 147 141 139
52 A 2/21/2012 Govindammal 128 120 102 135 115 114 110 135 126 127 120 124 124 116 116 113 120
53 B 1/29/2014 Ramya 135 135 118 144 133 112 128 131 139 146 137 133 131 132 129 131 113 122 125 130
54 B 1/6/2014 Deepa 134 134 114 148 120 108 99 102 148 148 153 151 154 146 152 141 134 139 142 132 110 122
55 B 5/15/2014 Padma 150 150 140 159 151 109 100 124 140 151 152 156 156 145 139 135 134 136
56 B 5/11/2014 Charumathi 145 145 135 154 146 104 95 119 135 146 147 151 151 140 134 130 129 131
57 B 2/23/2014 Ganesh 123 113 84 104 95 89 99 96 107 112 117 118 115 111 105 108 114
58 B 5/29/2014 Sasikala 120 102 96 107 110 104 97 94 97 118 115 113 106 107 101 97 100 111 125
59 B 5/31/2014 Selvi 125 118 102 121 105 101 121 122 131 124 127 128 120 138 114 123 114 116 113
60 A 6/1/2014 Menaka 124 123 105 140 105 88 97 103 126 127 112 11 114 101 107 119
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1 B 11/18/2013 Lalitha 82 80 77 86 81 61 62 67 63 63 63 53 69 69 67 71 74
2 A 11/21/2013
Nazina
Begum 86 85 83 93 83 76 86 85 83 88 89 89 91 90 66 71
3 A 11/21/2013 Anbarasan 86 84 83 93 83 76 83 85 88 88 89 89 91 90 66 84
4 A 11/22/2013 Ilakkiya 70 68 60 70 60 58 76 80 86 70 60 88 82 86 84 80 82 88
5 B 11/29/2013 Maheswari 113 108 101 101 97 96 91 96 85 85 82 83 102 102 98
6 B 1/7/2014
Saravana
kumar 73 80 69 87 76 58 58 46 57 58 62 69 68 64 65 63 64 66 61 80
7 A 1/9/2013 Lingaraj 78 75 64 86 79 70 74 82 90 90 92 88 77 78 75 81 74 71 79 79
8 B 1/10/2014 Radha 92 91 89 92 86 72 71 110 118 111 114 112 112 111 105 100 100 95 96 75 77
9 A 1/10/2014 Roja 79 79 83 98 78 72 71 91 102 102 103 94 86 89 84
10 A 1/11/2014 Nazima 78 77 77 85 75 79 99 91 86 77 88 84 79 79 80 79 66
11 A 1/21/2014 Mukesh 91 86 75 109 79 59 88 79 88 97 96 104 86 84 88 87 87
12 A 1/21/2014 Hemalatha 79 76 70 93 76 71 55 53 75 86 97 86 80 80 83
13 B 1/24/2014 Regina 92 89 72 94 84 73 87 100 102 106 102 93 95 93 84 88 58 71 69 88
14 A 1/29/2014 Elumalai 88 102 85 11 101 84 76 81 71 91 89 113 115 111 131 113 108 103
15 A 2/3/2014 Mariraj 82 82 63 75 73 77 72 73 78 72 61 57 63 63 63 65 68 67 70 73 69 67 66 66 65 62 71
16 B 2/6/2014 Revathy 78 88 68 97 86 81 87 93 88 82 76 73 65 68 66 75 73
17 A 2/12/2014 Selvi 78 77 68 90 66 51 60 66 85 84 74 73 77 64 74 79
18 A 2/19/2014 Tamaraiselvi 83 82 54 102 61 50 60 52 58 64 107 97 101 84 100 83 79 81
19 A 2/20/2014 Devika 81 80 70 85 70 63 61 60 66 116 88 83 92 104 92 81 79 68 82 76 81
20 B 2/22/2014 Vignesh 84 79 58 74 59 58 62 68 73 76 80 81 82 78 70 69 70
21 B 2/27/2014 Annapoorani 94 102 88 106 82 78 63 71 94 82 81 82 86 79 80 80 79
22 B 2/28/2014 Jainu 82 73 56 92 84 64 61 60 57 59 79 86 80 68 68 64 81
23 A 3/4/2014 Yamuna 93 83 73 90 71 67 69 86 88 88 82 80 74 74 74 77
24 A 3/9/2014 Jagadha 91 95 91 103 91 72 84 85 85 83 117 86 88 97 81 83 84 86
25 A 3/10/2014 Dharani 89 84 80 113 102 85 85 80 81 97 104 86 83 83 88 84 84
26 A 5/7/2014 Anusha 82 82 56 77 70 63 84 73 73 114 103 98 80 86 76 80 86
27 B 5/9/2014 Selvi 106 107 77 104 83 75 60 106 109 108 105 104 84 90 90 80 77 91 73 76 76
28 B 5/10/2014 Sindhu 70 65 65 85 85 74 51 58 54 83 83 89 85 87 89 89 73 79
29 B 3/11/2014 Balakrishnan 92 91 98 104 97 81 66 89 115 114 114 108 98 97 78 82 82
30 A 5/13/2014
Thasriya
nasllen 97 86 86 76 76 77 77 69 80 85 114 105 108 82 92 75 76 76
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31 B 5/17/2014 Sathya 79 79 69 84 86 71 60 78 86 93 89 84 86 85 81 81 79 78 79
32 B 5/20/2014 Uma 80 86 80 99 98 85 70 85 98 100 101 106 102 97 93 92 94 92
33 A 5/19/2014 Deepa 81 81 55 76 69 62 83 72 72 112 102 97 79 85 75 79 85
34 A 5/21/2014 Selvi 79 78 64 86 76 80 68 100 92 87 78 89 85 80 80 81 80
35 B 2/25/2014 Sampoorna 94 102 88 102 82 78 63 71 94 82 81 82 86 79 80 80 79
36 B 2/23/2014 Geetha 89 97 83 97 77 73 58 66 89 77 76 77 81 74 75 75 74
37 A 2/11/2014 Pankajam 79 78 71 86 76 80 68 100 92 87 78 89 85 80 80 81 80 67
38 A 2/6/2014 Rathinam 78 77 70 85 75 79 67 99 91 86 77 88 84 79 79 80 79 66
39 B 1/22/2014 Rajni 91 88 71 93 83 72 86 99 101 105 101 92 94 92 83 87 58 70 68 87
40 A 1/28/2014 Seetha 88 102 85 111 101 84 76 81 71 91 89 113 103 105 100 121 107 102 92 86
41 B 5/22/2014 Govindammal 83 82 80 90 88 80 75 64 64 61 64 64 66 83 68 68 79 78 82
42 A 3/5/2014 Ponmudi 92 82 72 89 70 66 68 85 87 87 81 79 73 73 73 76
43 B 5/15/2014 Kuppam 82 81 79 89 87 79 74 63 63 60 63 63 65 82 67 67 78 77 81
44 A 3/11/2014 Kavitha 90 94 90 91 90 71 83 84 84 82 116 85 87 96 80 82 83 85
45 A 2/14/2014 Rani 98 77 68 92 66 68 114 66 85 84 74 73 77 64 74 79 73 80
46 B 5/23/2014 Vinothavalli 89 89 70 96 79 70 70 88 92 92 93 91 90 90 86 84 83 84
47 B 5/23/2014 Rekha 88 88 69 95 78 69 69 87 91 91 92 90 89 89 85 83 82 83
48 B 1/10/2014 Sundaram 73 80 69 87 76 58 60 58 58 57 58 62 69 68 64 65 63 64 66
49 B 1/22/2014 Hemalatha 78 75 69 92 75 70 52 54 74 85 96 85 79 79 82 82
50 A 1/24/2014 Suresh 82 87 76 110 80 60 79 89 80 89 98 97 105 87 85 89 88 88
51 A 2/2/2014 Sarathy 88 102 85 111 101 84 76 81 71 91 89 113 103 105 100 121 102 92 86
52 A 2/21/2012 Govindammal 78 77 63 85 75 79 67 99 91 88 77 88 84 79 79 80 79
53 B 1/29/2014 Ramya 91 88 71 93 83 72 86 99 101 105 105 101 92 94 92 83 87 67 70 68 87
54 B 1/6/2014 Deepa 92 91 89 92 86 72 62 71 92 92 111 114 112 112 111 105 100 100 95 96 75 77
55 B 5/15/2014 Padma 80 86 80 99 98 85 70 85 98 100 101 106 102 97 93 92 94 92
56 B 5/11/2014 Charumathi 82 88 82 101 100 87 72 87 100 102 103 108 104 99 95 94 96 94
57 B 2/23/2014 Ganesh 84 79 58 74 59 58 62 68 73 76 80 81 82 78 70 69 70
58 B 5/29/2014 Sasikala 72 68 64 77 60 57 51 56 59 80 81 64 58 73 66 60 64 63 79
59 B 5/31/2014 Selvi 79 74 62 81 65 62 88 95 90 95 96 91 87 93 77 86 74 80 80
60 A 6/1/2014 Menaka 78 77 68 90 66 51 60 66 85 84 74 73 77 64 74 79
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1  B 11/18/2013 Lalitha 97 95 91 99 93 73 72 72 75 73 71 77 77 70 71 83 85
2  A 11/21/2013 Nazina Begum 102 99 97 107 99 90 98 97 97 102 102 101 103 103 95 94
3  A 11/21/2013 Anbarasan 102 99 97 107 97 90 97 100 102 101 102 101 103 103 95 97
4  A 11/22/2013 Ilakkiya 83 78 73 83 73 71 90 92 95 81 67 95 89 94 90 88 92 99
5  B 11/29/2013 Maheswari 129 121 116 116 111 109 102 100 95 95 93 94 119 112 113
6  B 1/7/2014 Saravana kumar 86 93 82 102 89 72 70 58 69 72 74 61 80 77 72 76 77 78 74 92
7  A 1/9/2013 Lingaraj 89 87 75 95 83 78 96 100 81 103 101 92 93 86 96 87 87 69 68
8  B 1/10/2014 Radha 108 107 98 108 97 83 81 132 122 124 123 123 124 115 113 111 108 108 83
9  A 1/10/2014 Roja 89 91 93 110 92 82 81 99 114 114 115 105 96 99
10 A 1/11/2014 Nazima 92 88 88 98 89 91 102 102 99 89 97 96 91 91 90 94 80
11 A 1/21/2014 Mukesh 104 104 86 123 92 70 101 91 101 110 108 115 98 95 101 101
12 A 1/21/2014 Hemalatha 93 92 86 108 91 85 67 63 86 99 107 97 91 92 98
13 B 1/24/2014 Regina 104 103 89 106 100 100 99 115 112 118 112 105 100 100 96 101 70 86 84 101
14 A 1/29/2014 Elumalai 105 125 94 128 112 95 86 90 81 101 101 124 113 115 111 131 113 108 103
15 A 2/3/2014 Mariraj 95 94 75 86 81 87 83 83 90 82 72 68 74 74 73 75 79 77 81 83 80 79 77 77 77 72 82
16 B 2/6/2014 Revathy 89 100 77 108 96 93 99 109 102 96 89 84 77 80 77 85 85
17 A 2/12/2014 Selvi 92 91 80 113 79 64 71 78 100 97 86 86 89 76 85 93
18 A 2/19/2014 Tamaraiselvi 96 95 64 119 71 61 72 63 68 86 125 116 118 96 115 94 100 91
19 A 2/20/2014 Devika 93 92 83 98 83 73 73 71 77 128 98 93 105 117 106 94 90 81 92 87 94
20 B 2/22/2014 Vignesh 96 92 67 85 70 68 74 77 84 87 91 93 93 89 83 83 84
21 B 2/27/2014 Annapoorani 118 141 114 117 102 92 72 90 118 103 98 100 102 92 98 95 92
22 B 2/28/2014 Jainu 92 88 70 104 96 77 74 73 69 70 91 97 91 81 82 80 94
23 A 3/4/2014 Yamuna 106 96 86 104 85 80 81 99 101 101 95 93 85 86 85 90
24 A 3/9/2014 Jagadha 107 111 102 118 105 81 96 95 95 93 132 98 99 107 93 94 94 98
25 A 3/10/2014 Dharani 103 98 95 130 117 96 96 91 92 108 116 99 94 95 100 96 96
26 A 5/7/2014 Anusha 94 94 69 93 82 75 97 85 88 127 121 111 93 97 93 93 97
27 B 5/9/2014 Selvi 124 125 88 119 94 86 67 117 124 121 118 119 101 102 102 90 87 103 84 87 87
28 B 5/10/2014 Sindhu 80 76 76 93 94 60 69 64 94 93 100 96 97 98 99 83 82
29 B 3/11/2014 Balakrishnan 108 109 105 127 106 88 71 97 128 127 128 121 107 108 86 91 91
30 A 5/13/2014 Thasriya nasllen 110 110 100 88 90 91 90 82 93 99 130 122 122 96 105 85 87 86
31 B 5/17/2014 Sathya 99 100 87 103 106 89 73 91 98 106 104 100 101 100 95 95 96 95 96
123
32 B 5/20/2014 Uma 102 110 101 118 116 76 81 98 102 117 118 123 120 113 108 106 107 107
33 A 5/19/2014 Deepa 93 93 68 92 81 74 97 84 87 126 120 110 92 96 92 92 96
34 A 5/21/2014 Selvi 93 88 76 99 90 92 82 103 103 100 90 98 97 92 92 91 95
35 B 2/25/2014 Sampoorna 117 140 113 121 101 91 71 90 118 103 98 100 102 92 98 95 92
36 B 2/23/2014 Geetha 111 134 107 115 95 85 65 84 112 97 92 94 96 86 92 89 86
37 A 2/11/2014 Pankajam 93 89 84 99 90 92 82 103 103 100 90 98 97 92 92 91 95 81
38 A 2/6/2014 Rathinam 92 88 83 98 89 91 81 102 102 99 89 97 96 91 91 90 94 80
39 B 1/22/2014 Rajni 104 103 89 106 100 100 99 115 112 118 112 105 108 100 96 101 70 86 84 101
40 A 1/28/2014 Seetha 105 125 94 128 112 95 86 90 81 101 101 124 113 115 111 131 119 113 108 103
41 B 5/22/2014 Govindammal 96 95 94 104 95 94 86 75 74 71 74 74 75 94 77 77 89 88 92
42 A 3/5/2014 Ponmudi 105 95 85 103 84 79 80 98 100 100 94 92 84 85 84 99
43 B 5/15/2014 Kuppam 96 95 94 104 95 94 86 75 74 71 74 74 75 94 77 77 89 88 92
44 A 3/11/2014 Kavitha 106 110 101 112 106 80 95 94 94 92 131 97 98 106 92 93 93 97
45 A 2/14/2014 Rani 92 91 80 109 79 79 125 78 100 96 86 86 89 76 85 93 86 95
46 B 5/23/2014 Vinothavalli 111 110 84 114 92 79 79 99 104 104 106 103 102 102 97 95 94 95
47 B 5/23/2014 Rekha 110 109 83 113 91 78 78 98 103 103 105 102 101 101 96 94 93 94
48 B 1/10/2014 Sundaram 86 93 82 102 89 72 73 70 70 69 72 74 61 80 77 77 76 77 78
49 B 1/22/2014 Hemalatha 92 91 85 107 90 84 68 62 85 98 106 96 90 91 97 97
50 A 1/24/2014 Suresh 95 105 87 124 93 71 91 102 92 102 111 109 116 99 96 102 102 102
51 A 2/2/2014 Sarathy 105 125 94 128 112 95 86 90 81 101 101 124 113 115 111 131 113 108 103
52 A 2/21/2012 Govindammal 92 87 75 98 89 91 81 102 102 99 89 97 96 91 91 90 94
53 B 1/29/2014 Ramya 104 103 89 106 100 100 99 115 112 118 112 105 100 100 96 101 80 86 84 101
54 B 1/6/2014 Deepa 108 107 98 108 97 83 73 81 108 108 122 124 123 123 124 115 113 111 108 108 83 93
55 B 5/15/2014 Padma 102 114 101 122 116 76 81 98 102 117 118 123 120 113 108 106 107 107
56 B 5/11/2014 Charumathi 101 113 102 123 117 77 82 99 103 118 119 124 121 114 109 107 108 108
57 B 2/23/2014 Ganesh 96 91 67 85 70 68 74 77 84 87 91 93 93 89 83 83 84
58 B 5/29/2014 Sasikala 88 80 75 88 77 69 65 67 72 93 93 88 78 85 78 74 79 76 94
59 B 5/31/2014 Selvi 91 88 75 94 78 70 98 105 103 106 105 103 98 105 88 97 86 92 91
60 A 6/1/2014 Menaka 92 91 80 113 79 64 71 78 100 97 86 86 89 76 85 93
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1  B 11/18/2013 Lalitha 39 31 37 38 37 38 39 38 37 39 39 38 37 38
2  A 11/21/2013 Nazina Begum 38 37 38 30 37 38 39 38 37 38 39 38 38
3  A 11/21/2013 Anbarasan 38 37 37 39 30 36 38 39 37 38 38 38 36
4  A 11/22/2013 Ilakkiya 38 38 39 38 39 36 37 39 38 39 30 37 38 38 38
5  B 11/29/2013 Maheswari 30 31 30 30 38 38 39 30 38 39 30 30
6  B 1/7/2014 Saravana kumar 39 38 39 36 38 39 30 37 38 30 36 39 38 37 39 30
7  A 1/9/2013 Lingaraj 33 30 38 37 38 39 30 33 35 33 31 39 30 31 30 39
8  B 1/10/2014 Radha 38 39 37 37 38 37 38 37 38 39 37 38 35 37 38 38 39 28 28
9  A 1/10/2014 Roja 38 36 35 37 32 35 34 36 35
10 A 1/11/2014 Nazima 38 39 30 34 32 31 30 30 38 39 39 39
11 A 1/21/2014 Mukesh 39 38 39 38 37 39 30 39 37 39 38 37 39
12 A 1/21/2014 Hemalatha 35 33 34 34 33 35 31 32 34 37 39
13 B 1/24/2014 Regina 38 36 35 39 36 37 38 34 33 34 37 38 36 38 37 38
14 A 1/29/2014 Elumalai 34 30 30 38 35 36 34 38 36 37 36 37 38 38
15 A 2/3/2014 Mariraj 33 39 37 30 30 31 30 39 31 36 33 31 30 36 35 35 34 36 34 34 35 30 27 29
16 B 2/6/2014 Revathy 30 31 32 37 34 37 30 34 37 35 39 38 39
17 A 2/12/2014 Selvi 34 34 36 37 34 34 33 35 38 31 30 31
18 A 2/19/2014 Tamaraiselvi 31 31 31 37 38 34 38 37 38 37 39 38 39 39 30
19 A 2/20/2014 Devika 33 34 37 34 35 32 36 34 30 32 35 34 30 30 30 30 34
20 B 2/22/2014 Vignesh 33 38 37 34 39 31 39 31 39 37 39 30 38
21 B 2/27/2014 Annapoorani 39 36 35 36 34 36 39 38 32 39 38 39 38 39
22 B 2/28/2014 Jainu 39 30 38 30 31 39 30 32 30 32 30 32 30 30 31 30
23 A 3/4/2014 Yamuna 30 38 39 39 29 34 36 35 33 36 34 30
24 A 3/9/2014 Jagadha 30 30 37 39 37 31 30 34 35 37 38 37 34 37
25 A 3/10/2014 Dharani 30 38 30 37 37 33 39 37 30 37 38 37 38
26 A 5/7/2014 Anusha 38 36 35 34 32 35 36 34 36 35 37 36 37
27 B 5/9/2014 Selvi 38 38 37 39 36 34 35 35 36 38 37 38 39 30 36 37
28 B 5/10/2014 Sindhu 30 39 36 34 38 35 36 35 38 35 38 34 35 34 35
29 B 3/11/2014 Balakrishnan 30 39 38 35 36 31 30 33 31 30 35 35
30 A 5/13/2014 Thasriya nasllen 38 37 36 38 39 35 34 38 39 38 37 39 38 35 34
31 B 5/17/2014 Sathya 38 37 34 35 37 36 37 38 37 36 38 37 36 36
32 B 5/20/2014 Uma 39 38 39 36 38 37 38 37 36 37 37 38 37 37
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33 A 5/19/2014 Deepa 38 36 35 34 32 35 35 36 37 36 37 37 36
34 A 5/21/2014 Selvi 38 38 39 30 34 34 33 34 35 35 37 38 36
35 B 2/25/2014 Sampoorna 39 36 35 36 34 36 30 38 32 39 38 39 38 39
36 B 2/23/2014 Geetha 39 36 35 36 34 36 39 38 32 39 38 39 38
37 A 2/11/2014 Pankajam 30 30 39 38 36 37 38 39 36 35 36 36 37 38
38 A 2/6/2014 Rathinam 38 38 37 37 36 35 38 39 39 38 38 39 37 37
39 B 1/22/2014 Rajni 38 36 35 39 36 37 38 34 33 34 37 38 36 38 37 38
40 A 1/28/2014 Seetha 34 30 30 38 35 36 34 38 36 37 36 37 38 38 38
41 B 5/22/2014 Govindammal 35 35 35 34 34 33 34 31 31 35 34 35 34 35 35 34 35
42 A 3/5/2014 Ponmudi 30 38 39 39 34 35 33 35 34 30
43 B 5/15/2014 Kuppam 34 33 34 32 30 38 39 30 32 31 30 37 38 37 36 35 39
44 A 3/11/2014 Kavitha 39 37 34 37 31 30 34 35 37 38 37 34 37
45 A 2/14/2014 Rani 34 34 36 37 34 34 33 35 33 35 33 31 30 31 30
46 B 5/23/2014 Vinothavalli 30 30 37 30 39 31 30 39 38 38 38 37 38
47 B 5/23/2014 Rekha 30 30 39 30 39 31 30 39 39 38 39 38 39 38
48 B 1/10/2014 Sundaram 38 39 30 39 39 39 38 35 36 35 35 38 38 38 35 38 30
49 B 1/22/2014 Hemalatha 35 34 33 34 33 35 31 32 34 37 39 38
50 A 1/24/2014 Suresh 39 38 39 38 39 38 36 35 38 39 38 37 39 35
51 A 2/2/2014 Sarathy 34 30 30 38 35 36 33 38 36 37 36 37 38 38 38
52 A 2/21/2012 Govindammal 38 38 39 30 34 34 33 34 35 35 36 38
53 B 1/29/2014 Ramya 38 36 35 34 39 36 37 38 37 39 37 36 38 39
54 B 1/6/2014 Deepa 37 38 39 36 35 36 35 34 38 39 38 39 38 38 37 36 39
55 B 5/15/2014 Padma 32 31 32 30 39 39 38 38 39 37 36 37 38 37
56 B 5/11/2014 Charumathi 30 30 31 39 38 37 38 39 38 39 38 38 39 39
57 B 2/23/2014 Ganesh 32 32 31 30 32 39 38 37 38 37 39 38
58 B 5/29/2014 Sasikala 33 30 39 38 37 39 37 36 38 39 35 34 35 37 38
59 B 5/31/2014 Selvi 31 30 30 30 31 38 39 38 39 30 37 38 37 39 30
60 A 6/1/2014 Menaka 34 34 36 37 34 34 33 35 38 31 30 31
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1 B 11/18/2013 Lalitha 3 3 3 0 3 3 3 3 0 3 3 3
Skin
closure
2 A 11/21/2013 Nazina Begum 3 3 3 3 3 3 3 3 3 3 3
Skin
Closure
3 A 11/21/2013 Anbarasan 3 3 3 3 3 3 3 3 3 3 3
Skin
Closure
4 A 11/22/2013 Ilakkiya 3 3 3 3 3 3 3 3 3 3 3 3
Skin
closure
5 B 11/29/2013 Maheswari 3 3 3 3 3 3 0 3 3 3
Skin
closure
6 B 1/7/2014 Saravana kumar 3 3 3 3 0 3 3 3 3 3 3 3 3
Skin
closure
7 A 1/9/2013 Lingaraj 3 3 3 3 3 3 3 3 3 3 3 3 3
Skin
closure
8 B 1/10/2014 Radha 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3
skin
closure
9 A 1/10/2014 Roja 3 3 3 3 3 3 3 3
Skin
closure
10 A 1/11/2014 Nazima 3 3 3 3 3 3 3 3 3 3 3 3
Skin
closure
11 A 1/21/2014 Mukesh 3 3 3 3 3 3 3 3 3 3 3
Skin
Closure
12 A 1/21/2014 Hemalatha 3 3 3 3 3 3 3 3 3 3
Skin
closure
13 B 1/24/2014 Regina 3 3 3 3 3 3 3 3 3 3 3 3 3 0
Skin
closure
14 A 1/29/2014 Elumalai 3 3 3 3 3 3 3 3 3 3 3 3 3 3
Skin
closure
15 A 2/3/2014 Mariraj 3 3 3 3 3 3 3 3 0 3 3 3 3 3 3 3 3 3 3 3 3 3
Skin
closure
16 B 2/6/2014 Revathy 3 3 3 3 3 3 3 3 3 3 3
Skin
Closure
17 A 2/12/2014 Selvi 3 3 3 3 3 3 3 3 3 3 3
Skin
Closure
18 A 2/19/2014 Tamaraiselvi 3 3 0 3 0 0 3 3 3 3 3 3 3 3
Skin
closure
19 A 2/20/2014 Devika 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3
skin
closure
20 B 2/22/2014 Vignesh 3 3 0 3 3 3 3 3 3 3 3
Skin
Closure
21 B 2/27/2014 Annapoorani 3 3 3 0 3 3 3 3 3 3 3 3
Skin
closure
22 B 2/28/2014 Jainu 3 3 3 3 3 3 3 3 3 3 3 3
Skin
closure
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23 A 3/4/2014 Yamuna 3 3 3 3 3 3 3 3 3 3 3
Skin
Closure
24 A 3/9/2014 Jagadha 3 3 3 3 3 3 3 3 3 3 3 3 3
Skin
closure
25 A 3/10/2014 Dharani 3 3 3 3 3 3 3 3 3 3 3 3
Skin
closure
26 A 5/7/2014 Anusha 3 3 3 3 3 3 3 3 3 3 3 3
Skin
closure
27 B 5/9/2014 Selvi 3 3 3 0 3 3 3 3 3 3 3 3 3 0 3 3
skin
closure
28 B 5/10/2014 Sindhu 3 3 3 3 3 3 3 3 3 3 3 3
Skin
closure
29 B 3/11/2014 Balakrishnan 3 3 3 0 3 3 3 3 3 3 3 3
Skin
closure
30 A 5/13/2014 Thasriya nasllen 3 3 3 3 3 3 3 3 3 3 3 3 3
Skin
closure
31
B 5/17/2014 Sathya 3 3 3 0 3 3 3 3 3 3 3 3 3 3
Skin
closure
32 B 5/20/2014 Uma 3 3 0 3 3 3 3 3 3 3 3 3 3
Skin
closure
33 A 5/19/2014 Deepa 3 3 3 3 3 3 3 3 3 3 3 3
Skin
closure
34 A 5/21/2014 Selvi 3 3 3 3 3 3 3 3 3 3 3 3
Skin
closure
35 B 2/25/2014 Sampoorna 3 3 3 0 3 3 3 3 3 3 3 3
Skin
closure
36 B 2/23/2014 Geetha 3 3 3 0 3 3 3 3 3 3 3 3
Skin
closure
37 A 2/11/2014 Pankajam 3 3 3 3 3 3 3 3 3 3 3 3 3
Skin
closure
38 A 2/6/2014 Rathinam 3 3 3 3 3 3 3 3 3 3 3 3 3
Skin
closure
39 B 1/22/2014 Rajni 3 3 3 3 3 3 3 3 3 3 3 3 3 0
Skin
closure
40 A 1/28/2014 Seetha 3 3 3 3 3 3 3 3 3 3 3 3 3 3
Skin
closure
41 B 5/22/2014 Govindammal 3 3 3 3 3 3 0 3 3 3 3 3 3 3
Skin
closure
42 A 3/5/2014 Ponmudi 3 3 3 3 3 3 3 3 3 3 3
Skin
Closure
43 B 5/15/2014 Kuppam 3 3 3 3 3 3 0 3 3 3 3 3 3 3
Skin
closure
44 A 3/11/2014 Kavitha 3 3 3 3 3 3 3 3 3 3 3 3 3
Skin
closure
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45 A 2/14/2014 Rani 3 3 3 3 3 3 3 3 3 3 3 3 3
Skin
closure
46 B 5/23/2014 Vinothavalli 3 3 0 0 3 3 3 3 3 3 3 3 3
Skin
closure
47 B 5/23/2014 Rekha 3 3 0 0 3 3 3 3 3 3 3 3 3
Skin
closure
48 B 1/10/2014 Sundaram 3 3 3 3 3 3 3 3 3 3 3 3 3 3
Skin
closure
49 B 1/22/2014 Hemalatha 3 3 3 3 3 3 3 3 3 3 3
Skin
Closure
50 A 1/24/2014 Suresh 3 3 3 3 3 3 3 3 3 3 3 3 Skin closure
51 A 2/2/2014 Sarathy 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3
Skin
closure
52
A 2/21/2012 Govindammal 3 3 3 3 3 3 3 3 3 3 3 3
Skin
closure
53 B 1/29/2014 Ramya 3 3 3 3 3 3 3 3 3 3 3 3 3 3 Skin closure
54 B 1/6/2014 Deepa 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3
Skin
closure
55 B 5/15/2014 Padma 3 3 0 3 3 3 3 3 3 3 3 3 3
Skin
closure
56 B 5/11/2014 Charumathi 3 3 0 3 3 3 3 3 3 3 3 3 3
Skin
closure
57 B 2/23/2014 Ganesh 3 3 0 3 3 3 3 3 3 3 3
Skin
Closure
58 B 5/29/2014 Sasikala 3 3 3 3 3 3 3 3 3 3 3 3 3 3
Skin
closure
59 B 5/31/2014 Selvi 3 3 3 3 3 3 3 3 3 3 3 3 3 3
Skin
closure
60 A 6/1/2014 Menaka 3 3 3 3 3 3 3 3 3 3 3
Skin
Closure
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1  B 11/18/2013 Lalitha
2  A 11/21/2013 Nazina Begum
3  A 11/21/2013 Anbarasan
4  A 11/22/2013 Ilakkiya
5  B 11/29/2013 Maheswari
6  B 1/7/2014 Saravana kumar
7  A 1/9/2013 Lingaraj
8  B 1/10/2014 Radha 30
9  A 1/10/2014 Roja 25
10  A 1/11/2014 Nazima
11  A 1/21/2014 Mukesh
12  A 1/21/2014 Hemalatha
13  B 1/24/2014 Regina
14  A 1/29/2014 Elumalai 30
15  A 2/3/2014 Mariraj
16  B 2/6/2014 Revathy
17  A 2/12/2014 Selvi
18  A 2/19/2014 Tamaraiselvi 25 25
19  A 2/20/2014 Devika 30
20  B 2/22/2014 Vignesh
21  B 2/27/2014 Annapoorani
22  B 2/28/2014 Jainu
23  A 3/4/2014 Yamuna
24  A 3/9/2014 Jagadha 25
25  A 3/10/2014 Dharani 30
26  A 5/7/2014 Anusha 25 25
27  B 5/9/2014 Selvi
28  B 5/10/2014 Sindhu
29  B 3/11/2014 Balakrishnan
30  A 5/13/2014 Thasriya nasllen 30
31  B 5/17/2014 Sathya
32  B 5/20/2014 Uma
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33  A 5/19/2014 Deepa 30 30
34  A 5/21/2014 Selvi
35  B 2/25/2014 Sampoorna
36  B 2/23/2014 Geetha
37  A 2/11/2014 Pankajam
38  A 2/6/2014 Rathinam
39  B 1/22/2014 Rajni
40  A 1/28/2014 Seetha 30
41  B 5/22/2014 Govindammal
42  A 3/5/2014 Ponmudi
43  B 5/15/2014 Kuppam
44  A 3/11/2014 Kavitha 25
45  A 2/14/2014 Rani 30
46  B 5/23/2014 Vinothavalli
47  B 5/23/2014 Rekha
48  B 1/10/2014 Sundaram
49  B 1/22/2014 Hemalatha
50  A 1/24/2014 Suresh 30
51  A 2/2/2014 Sarathy 30
52  A 2/21/2012 Govindammal
53  B 1/29/2014 Ramya
54  B 1/6/2014 Deepa
55  B 5/15/2014 Padma
56  B 5/11/2014 Charumathi
57  B 2/23/2014 Ganesh
58  B 5/29/2014 Sasikala
59  B 5/31/2014 Selvi
60  A 6/1/2014 Menaka
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1 B 11/18/2013 Lalitha 200 ml 200 ml
2 A 11/21/2013 Nazina Begum
3 A 11/21/2013 Anbarasan
4 A 11/22/2013 Ilakkiya
5 B 11/29/2013 Maheswari 200 ml
6 B 1/7/2014 Saravana kumar
7 A 1/9/2013 Lingaraj
8 B 1/10/2014 Radha
9 A 1/10/2014 Roja
10 A 1/11/2014 Nazima
11 A 1/21/2014 Mukesh
12 A 1/21/2014 Hemalatha
13 B 1/24/2014 Regina 200 ml
14 A 1/29/2014 Elumalai
15 A 2/3/2014 Mariraj 200 ml
16 B 2/6/2014 Revathy
17 A 2/12/2014 Selvi
18 A 2/19/2014 Tamaraiselvi
19 A 2/20/2014 Devika
20 B 2/22/2014 Vignesh 200 ml
21 B 2/27/2014 Annapoorani 200 ml
22 B 2/28/2014 Jainu
23 A 3/4/2014 Yamuna
24 A 3/9/2014 Jagadha
25 A 3/10/2014 Dharani
26 A 5/7/2014 Anusha
27 B 5/9/2014 Selvi 200 ml 200 ml
28 B 5/10/2014 Sindhu
29 B 3/11/2014 Balakrishnan 200 ml
30 A 5/13/2014 Thasriya nasllen
31 B 5/17/2014 Sathya 200 ml
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32 B 5/20/2014 Uma 200 ml
33 A 5/19/2014 Deepa
34 A 5/21/2014 Selvi
35 B 2/25/2014 Sampoorna 200 ml
36 B 2/23/2014 Geetha 200 ml
37 A 2/11/2014 Pankajam
38 A 2/6/2014 Rathinam
39 B 1/22/2014 Rajni 200 ml
40 A 1/28/2014 Seetha
41 B 5/22/2014 Govindammal 200 ml
42 A 3/5/2014 Ponmudi
43 B 5/15/2014 Kuppam 200 ml
44 A 3/11/2014 Kavitha
45 A 2/14/2014 Rani
46 B 5/23/2014 Vinothavalli 200 ml 200 ml
47 B 5/23/2014 Rekha 200 ml 200 ml
48 B 1/10/2014 Sundaram
49 B 1/22/2014 Hemalatha
50 A 1/24/2014 Suresh
51 A 2/2/2014 Sarathy
52 A 2/21/2012 Govindammal
53 B 1/29/2014 Ramya
54 B 1/6/2014 Deepa
55 B 5/15/2014 Padma 200 ml
56 B 5/11/2014 Charumathi 200 ml
57 B 2/23/2014 Ganesh 200 ml
58 B 5/29/2014 Sasikala
59 B 5/31/2014 Selvi
60 A 6/1/2014 Menaka
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1  B 11/18/2013 Lalitha 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6
Stopped
-skin
closure
2  A 11/21/2013 Nazina Begum 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2
Stopped
- skin
closure
3  A 11/21/2013 Anbarasan 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2
Stopped
- skin
closure
4  A 11/22/2013 Ilakkiya 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2
Stopped
-skin
closure
5  B 11/29/2013 Maheswari 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6
Stopped
- skin
closure
6  B 1/7/2014
Saravana
kumar 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6
Stopped
-skin
closure
7  A 1/9/2013 Lingaraj 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2
Stopped
-skin
closure
8
B 1/10/2014 Radha 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6
Stopped
- skin
closure
9  A 1/10/2014 Roja 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2
Stopped
-skin
closure
10 A 1/11/2014 Nazima 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2
Stopped
-skin
closure
11 A 1/21/2014 Mukesh 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2
Stopped
-skin
closure
12 A 1/21/2014 Hemalatha 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2
stopped
- skin
closure
13 B 1/24/2014 Regina 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6
Stopped
-skin
closure
14 A 1/29/2014 Elumalai 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2
stopped
-skin
closure
15 A 2/3/2014 Mariraj 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2
Stopped
-skin
closure
16 B 2/6/2014 Revathy 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6
Stopped
- skin
closure
17 A 2/12/2014 Selvi 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2
Stopped
- skin
closure - - -
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18 A 2/19/2014 Tamaraiselvi 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2
Stopped
-skin
closure
19 A 2/20/2014 Devika 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2
Stopped
- skin
closure
20 B 2/22/2014 Vignesh 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6
Stopped
- skin
closure
21 B 2/27/2014 Annapoorani 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6
Stopped
-skin
closure
22 B 2/28/2014 Jainu 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6
Stopped
-skin
closure
23 A 3/4/2014 Yamuna 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2
Stopped
- skin
closure
24 A 3/9/2014 Jagadha 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2
Stopped
-skin
closure
25 A 3/10/2014 Dharani 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2
Stopped
-skin
closure
26 A 5/7/2014 Anusha 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2
Stopped
-skin
closure
27 B 5/9/2014 Selvi 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6
Stopped
- skin
closure
28 B 5/10/2014 Sindhu 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6
Stopped
-skin
closure
29 B 3/11/2014 Balakrishnan 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6
Stopped
-skin
closure
30 A 5/13/2014
Thasriya
nasllen 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2
Stopped
-skin
closure
31 B 5/17/2014 Sathya 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6
Stopped
-skin
closure
32 B 5/20/2014 Uma 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6
Stopped
-skin
closure
33 A 5/19/2014 Deepa 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2
Stopped
-skin
closure
34 A 5/21/2014 Selvi 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2
Stopped
-skin
closure
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35 B 2/25/2014 Sampoorna 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6
Stopped
-skin
closure
36 B 2/23/2014 Geetha 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6
Stopped
-skin
closure
37 A 2/11/2014 Pankajam 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2
Stopped
-skin
closure
38 A 2/6/2014 Rathinam 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2
Stopped
-skin
closure
39 B 1/22/2014 Rajni 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6
Stopped
-skin
closure
40 A 1/28/2014 Seetha 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2
Stopped
-skin
closure
41 B 5/22/2014 Govindammal 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6
Stopped
-skin
closure
42
A 3/5/2014 Ponmudi 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2
Stopped
- skin
closure
43 B 5/15/2014 Kuppam 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6
Stopped
-skin
closure
44 A 3/11/2014 Kavitha 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2
Stopped
-skin
closure
45 A 2/14/2014 Rani 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2
Stopped
-skin
closure
46 B 5/23/2014 Vinothavalli 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6
Stopped
-skin
closure
47 B 5/23/2014 Rekha 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6
Stopped
-skin
closure
48 B 1/10/2014 Sundaram 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6
Stopped
-skin
closure
49 B 1/22/2014 Hemalatha 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6
Stopped
- skin
closure
50 A 1/24/2014 Suresh 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2
Stopped
-skin
closure
51 A 2/2/2014 Sarathy 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2
Stopped
-skin
closure
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52 A 2/21/2012 Govindammal 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2
Stopped
-skin
closure
53 B 1/29/2014 Ramya 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6
Stopped
-skin
closure
54 B 1/6/2014 Deepa 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6
Stopped
- skin
closure
55 B 5/15/2014 Padma 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6
Stopped
-skin
closure
56 B 5/11/2014 Charumathi 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6
Stopped
-skin
closure
57 B 2/23/2014 Ganesh 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6
Stopped
- skin
closure
58
B 5/29/2014 Sasikala 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6
Stopped
-skin
closure
59 B 5/31/2014 Selvi 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6
Stopped
-skin
closure
60 A 6/1/2014 Menaka 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2
Stopped
- skin
closure - - -
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SL No. Group Date Name
Duration to
Recovery
(Ability to obey
commands )
Duration to Tracheal
Extubation (min )
Post extubation
Sedation Score
( RAMSAY )
Average Inspiratory Desflurane
Concentration Total Fentanyl
Hypotension
episodes
Fentanyl
bolus
1  B 11/18/2013 Lalitha 17 19 2 2.33 60 2 0
2  A 11/21/2013 Nazina Begum 23 25 2 2.65 60 0 0
3  A 11/21/2013 Anbarasan 21 23 2 2.65 70 0 0
4  A 11/22/2013 Ilakkiya 17 20 2 2.68 50 0 0
5  B 11/29/2013 Maheswari 17 19 2 2.4 60 1 0
6  B 1/7/2014 Saravana kumar 16 20 3 2.57 60 0 0
7  A 1/9/2013 Lingaraj 7 11 2 2.714 50 0 0
8  B 1/10/2014 Radha 20 24 2 2.78 90 0 1
9  A 1/10/2014 Roja 16 20 2 2.45 75 0 1
10  A 1/11/2014 Nazima 14 16 2 2.68 60 0 0
11  A 1/21/2014 Mukesh 18 22 2 2.65 60 0 0
12  A 1/21/2014 Hemalatha 9 13 2 2.6 60 0 0
13  B 1/24/2014 Regina 16 20 3 2.48 50 1 0
14  A 1/29/2014 Elumalai 11 15 2 2.74 80 0 1
15  A 2/3/2014 Mariraj 16 18 2 2.85 75 1 0
16  B 2/6/2014 Revathy 18 21 2 2.65 50 0 0
17  A 2/12/2014 Selvi 11 13 2 2.65 60 0 0
18  A 2/19/2014 Tamaraiselvi 12 15 2 2.35 100 0 2
19  A 2/20/2014 Devika 12 14 2 2.78 100 0 1
20  B 2/22/2014 Vignesh 17 20 2 2.47 60 1 0
21  B 2/27/2014 Annapoorani 18 22 3 2.53 60 1 0
22  B 2/28/2014 Jainu 18 22 3 2.68 50 0 0
23  A 3/4/2014 Yamuna 15 17 2 2.65 50 0 0
24  A 3/9/2014 Jagadha 16 19 2 2.71 75 0 1
25  A 3/10/2014 Dharani 15 19 2 2.68 90 0 1
26  A 5/7/2014 Anusha 14 18 2 2.68 100 0 2
27  B 5/9/2014 Selvi 18 21 2 2.44 60 2 0
28  B 5/10/2014 Sindhu 17 20 2 2.68 50 0 0
29  B 3/11/2014 Balakrishnan 18 20 2 2.53 75 1 0
30  A 5/13/2014 Thasriya nasllen 15 17 2 2.71 90 0 1
31  B 5/17/2014 Sathya 18 22 2 2.61 60 1 0
32  B 5/20/2014 Uma 16 19 3 2.57 60 1 0
33  A 5/19/2014 Deepa 15 18 2 2.68 120 0 2
34  A 5/21/2014 Selvi 14 18 2 2.68 60 0 0
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SL No. Group Date Name
Duration to
Recovery
(Ability to obey
commands )
Duration to Tracheal
Extubation (min )
Post extubation
Sedation Score
( RAMSAY )
Average Inspiratory Desflurane
Concentration Total Fentanyl
Hypotension
episodes
Fentanyl
bolus
35  B 2/25/2014 Sampoorna 17 21 2 2.53 60 1 0
36  B 2/23/2014 Geetha 18 22 2 2.53 60 1 0
37  A 2/11/2014 Pankajam 15 17 2 2.71 65 0 0
38  A 2/6/2014 Rathinam 14 16 2 2.71 60 0 0
39  B 1/22/2014 Rajni 16 19 2 2.48 60 1 0
40  A 1/28/2014 Seetha 14 17 2 2.74 90 0 1
41  B 5/22/2014 Govindammal 16 19 2 2.61 60 1 0
42  A 3/5/2014 Ponmudi 13 16 2 2.65 50 0 0
43  B 5/15/2014 Kuppam 15 19 2 2.61 65 1 0
44  A 3/11/2014 Kavitha 14 16 2 2.71 75 0 0
45  A 2/14/2014 Rani 15 17 2 2.71 90 0 1
46  B 5/23/2014 Vinothavalli 16 20 2 2.41 60 2 1
47  B 5/23/2014 Rekha 15 18 2 2.42 60 2 0
48  B 1/10/2014 Sundaram 16 19 2 2.74 60 0 0
49  B 1/22/2014 Hemalatha 18 22 2 2.65 60 0 0
50  A 1/24/2014 Suresh 15 17 2 2.68 90 0 1
51  A 2/2/2014 Sarathy 14 17 2 2.76 90 0 1
52  A 2/21/2012 Govindammal 13 17 2 2.68 60 0 0
53  B 1/29/2014 Ramya 16 20 2 2.74 50 0 0
54  B 1/6/2014 Deepa 17 21 2 2.76 60 0 0
55  B 5/15/2014 Padma 15 18 2 2.57 60 1 0
56  B 5/11/2014 Charumathi 16 19 2 2.56 60 1 0
57  B 2/23/2014 Ganesh 17 20 2 2.43 70 1 0
58  B 5/29/2014 Sasikala 18 20 2 2.74 50 0 0
59  B 5/31/2014 Selvi 16 19 2 2.74 60 0 0
60  A 6/1/2014 Menaka 11 13 2 2.65 60 0 0
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